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ABSTRACT
COMBINATION REGIMENS USING DIETARY COMPONENTS FOR THE
CHEMOPREVENTION OF COLORECTAL CANCER
AND INFLAMMATION
SEPTEMBER 2018
CHRISTINA DIMARCO-CROOK, B.S., IMMACULATA UNIVERSITY
M.S., DREXEL UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Hang Xiao

Dietary components have been found to effectively modulate multiple deregulated
signaling pathways associated with the initiation and progression of carcinogenesis and
inflammation in cellular and animal models. However, clinical studies have shown
mixed results when examining the efficacy of individual dietary components, perhaps
suggestive of the synergism that exists between multiple components within a particular
food and the diet as a whole. Additional research is needed to identify and characterize
the unknown interactions and potential chemopreventive and anti-inflammatory
properties within combination regimens using dietary components.
Nobiletin a polymethoxyflavone (PMF) found primarily in the peel of sweet (C.
sinensis) and bitter (C. aurantium) orange has demonstrated significant anti-cancer and
anti-inflammatory effects in both cellular and animal models of colon cancer; therefore it
is important to investigate the biological activities and interactions of its metabolites with
other dietary components in order to better understand the possible mechanisms of
nobiletin in vivo. One of the primary metabolites of nobiletin in the mouse 3',4'didemethylnobiletin (DDMN), has been identified as the metabolite with the strongest
anti-proliferative effects in HCT116 wild-type p53 colon cancer cells. Colonic
concentration of nobiletin in the mouse is also much lower than its primary metabolites,
vi

of which DDMN is reported to exhibit stronger anti-cancer and anti-inflammatory effects
than its parent compound nobiletin. In addition, curcumin, apigenin and luteolin have
each been shown individually to exhibit significant anti-carcinogenic and antiinflammatory effects in various colon cancer model systems; however the interaction of
these dietary components in combination with DDMN has yet to be explored. Our results
find for the first time apigenin or luteolin, two flavones though similar in structure, to
have strikingly different responses when combined with DDMN in HCT116 wild-type
p53 colon cancer cells. Apigenin and DDMN are additive in combination with no
apparent interaction whereas luteolin when combined with DDMN exhibits an
antagonistic response with diminished anti-proliferative effects. Remarkably, in sharp
contrast to these findings the combination of curcumin and DDMN in HCT116 wild-type
p53 colon cancer cells demonstrates strong synergism with enhanced anti-proliferative
effects which greatly exceed the effects of individual treatments.
Additional examination of the synergistic combination of curcumin and DDMN
reveals significant cell cycle arrest and extensive apoptosis induced by the combination,
which were much stronger than the effects induced by the treatments with curcumin or
DDMN alone. Proteins associated with cell cycle arrest and apoptosis were analyzed by
Western Blot to confirm the change in expression of these proteins were much greater in
response to the combination treatment of curcumin and DDMN than each compound
alone. The synergy between curcumin and DDMN offers a possible novel mechanism for
nobiletin in combination with curcumin and warrants further investigation on their
combination to determine its chemopreventive and anti-inflammatory potential for colon
cancer in vivo.
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CHAPTER 1
REVIEW OF COMBINATION REGIMENS USING DIETARY COMPONENTS
FOR CANCER CHEMOPREVENTION

1.1

Abstract
Chemopreventive agents that the general population can consume for prolonged

periods of time with minimal risk of any side effects are of great interest to all in search
of a solution to the pervasive incidence of cancer. Dietary bioactive components have
been found to modulate many deregulated molecular pathways associated with the
initiation and progression of different types of cancer. Combination regimens with
dietary bioactive components are a promising strategy for cancer chemoprevention
because they may offer enhanced protective effects against cancer development but cause
little or no adverse effects. This article provides an overview of studies examining the
combination of dietary bioactive components for the chemoprevention of major types of
cancer. A better understanding of existing research on the combination of dietary
bioactive components will provide an important basis for the rational design of future
combination studies and the successful development of cancer chemoprevention
strategies.

1.2

Keywords

Dietary bioactive components, cancer chemoprevention, combination, synergy, whole
foods, colorectal cancer, prostate cancer, breast cancer, lung cancer, dietary supplements
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1.3

Introduction
Cancer is currently estimated to be responsible for one out of every four deaths in

the United States, a staggering number that reflects its far-reaching impact on society
(Jemal, Siegal et al. 2010). Although many advances have been made in the early
diagnosis and treatment of cancer, significant challenges to lowering cancer mortality
rates still remain. Accumulating evidence suggests that a promising strategy for
controlling cancer mortality rates is to prevent cancer from progressing to the advanced
malignant stages during which available treatment options are very limited. Cancer
chemoprevention is the use of natural or synthetic chemicals to reverse, suppress, or
prevent cancer development, thereby reducing an individual’s risk of cancer (Greenwald
2002). Dietary bioactive components have been investigated intensely for their potential
chemopreventive effects in different cancers. One major advantage of dietary
components as chemopreventive agents is that they generally have none or few of the
adverse effects frequently associated with pharmaceutical drugs after long-term
administration (Chen and Kong 2005; Ramos 2008; Davis, Emenaker et al. 2010;
Neergheen, Bahorun et al. 2010).
There is a growing body of evidence suggesting that the combination of cancer
chemopreventive agents with distinct mechanisms of action may produce a synergistic
type of interaction (Xiao and Yang 2008). The synergy among these agents can result in
considerably stronger cancer chemopreventive effects than those produced by each agent
individually. The enhanced efficacy of the combination regimen can also lower the dose
required for each agent in the combination which lowers the cost of the regimen and
offers a positive economic impact on society. Moreover, the lowered doses of

2

chemopreventive agents can potentially reduce or eliminate unwanted side effects
frequently associated with long-term administration of high-dose chemopreventive
agents. Numerous studies have explored the benefits of combining multiple
pharmaceutical drugs and combining dietary bioactive components with pharmaceutical
drugs to fight cancer (Schwartz, Birk et al. 2004; Tsuda, Ohshima et al. 2004;
Constantinou, White et al. 2005; Fresco, Borges et al. 2006; Martin 2006; Xiao and Yang
2008). However, less is understood about the combination of dietary bioactive
components for cancer chemoprevention. Herein, the combination studies on dietary
bioactive components are reviewed to investigate their ability to alter the pathology of
cancer. The principle and methods of determining the modes of interaction (i.e.,
synergistic, additive, and antagonistic) among multiple agents have been discussed
elsewhere (Greco, Bravo et al. 1995; Chou 2006; Lee, Kong et al. 2007). In this review,
the interaction among dietary bioactive components is examined on the basis of the
combination index (CI) or relevant statistical analyses (Xiao and Yang 2008). This
review summarizes existing research for the potential use of dietary bioactive
components in combination for cancer chemoprevention.

1.4

Colorectal Cancer
Accumulating research in colorectal cancer models suggests dietary bioactive

components in combination may enhance the anticarcinogenic effects attributed to each
individual component (Table 1.1). The estimated transition from precancerous cells to a
malignant colorectal tumor takes, on average, 10-15 years (Boursi and Arber 2007).
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Aberrant crypt foci (ACF) are believed to be the first identifiable precursor lesions of
colorectal cancer (Bird 1995).

1.4.1

Aberrant Crypt Foci (ACF)and Familial Adenomatous Polyposis (FAP)
The chemopreventive efficacy of curcumin (a major bioactive component found

in turmeric), green tea catechins [mainly (-)-epigallocatechin-3-gallate, EGCG], and their
combination was determined in male Wistar rats in which colon carcinogenesis was
induced by 1,2-dimethylhydrazine (Xu, Ren et al. 2010). After 12 weeks of dietary
treatments, the formation of colonic ACF was significantly decreased by the combination
treatment of curcumin and tea catechins. This inhibitory effect was stronger than that of
the treatments with individual components. Furthermore, following 32 weeks of dietary
treatments, the colonic tumor incidence of the combination treatment group was
significantly lower than that of the curcumin or catechin treatment groups. These results
suggest that the combination treatment with curcumin and green tea catechins produces
enhanced inhibitory effects on both the initiation and progression stages of colon
carcinogenesis. Studies using whole foods in combination have also demonstrated strong
anticarcinogenic effects on ACF formation (Challa, Rao et al. 1997; Sengupta, Ghosh et
al. 2004). A study using the azoxymethane-induced rat model showed that the garlic and
tomato combination dietary treatment produced a stronger effect on the inhibition of
abnormal cell proliferation, the induction of apoptosis, and greater decreases in ACF
formation than garlic or tomato alone (Sengupta, Ghosh et al. 2004). The pronounced
inhibitory effect on ACF formation by the combination of garlic and tomato has been
attributed in part to the reduction of cyclo-oxygenase-2 (COX-2) and induction of

4

Table 1.1 Studies examining the combination of dietary bioactive components on
colorectal cancer
Combination
Model System
References
Treatment
Mechanism/Effect
Indol-3-carbinol
Genistein*

HT29 colon cancer cells, ↓autophagy, ↓Akt
phosphorylation, ↑caspase-dependent
apoptosis

Nakamura
et al

Sulforaphane, 3,3'diindolymethane*

HCT116 Clone colon cancer cells,
↑G2/M cell-cycle arrest, ↓cell proliferation

Pappa et al

Indole-3-carbinol, 4methoxyindole-3carbinol

DLD-1 and HCT116 colon cancer cells,
↓cell proliferation

Kronbak et al

Isothiocyanates
Indoles

LS-174 colon cancer cells,
↓single-strand DNA breaks

Bonnesen et al

Resveratrol, Chrysin,
Curcumin

Caco-2 colon cancer cells,
↑UGT1A1↓cell proliferation

Iwuchukwu
et al

Butyrate
Carnitine

Caco-2 colon cancer cells,
↓Cox-2, ↑apoptosis, ↓cell proliferation

Roy et al

Resveratrol
Grapeseed extract*

HCT116 colon cancer cells, ↑, ↑Bax,
↓Bcl-2, ↑apoptosis, ↓cell proliferation

Radhakrishnan
et al

Resveratrol
Curcumin*

HCT116 colon cancer cells, ↓pEGFR,
↓pHER-2, ↓pHER-3, ↓pIGF-IR, ↑S phase
cell-cycle arrest

Majumdar
et al

Total Cranberry Extract
Polyphenols

HCT116 and HT29 colon cancer cells,
↓cell proliferation

Seeram et al

Pomegranate Juice
Polyphenols

HCT116 and HT29 colon cancer cells, ↓cell
proliferation, ↑apoptosis, ↓lipid peroxidation

Seeram et al

Sulforaphane
Apigenin

CaCo-2 colon cancer cells,
↑UGT1A1

Svehlikova
et al

Docosahexaenoic acid
(DHA), Butyrate

HCT116 colon cancer cells,
↑apoptosis↑ mitochondrial Ca2+

Kolar et al
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Table 1.1 Continued
Combination
Treatment

Model System
Mechanism/Effect

References

Sulforaphane, Iberin
Selenium

Caco-2 and HCT116 colon cancer cells,
No effect on abnormal methylation

Barrera et al

Green Tea
Selenium

Azoxymethane treated Sprague-Dawley rats,
↓DNMT1, ↑histone H3 acetylation, ↓ACF,
↓cell proliferation, ↓CyclinD1, ↑SFRP5

Hu et al

β-ionone
geraniol

Dimethylhydrazine induced Wistar rats,
↓bioavailability

Viera et al

Sulforaphane
Dibenzoylmethane

ApcMin/+ mice,
No significant effects as compared to
individual components

Shen et al

(-)-Epigallocatechin-3gallate, Fish oil

ApcMin/+ mice, ↓tumor occurrence, ↓large
tumors, ↓PGE2, ↓nuclear β-catenin, ↓p-Akt

Bose et al

Diosmin
Hesperidin

Azoxymethane treated F344 rats,
No significant effects as compared to
individual components

Tanaka et al

Curcumin
Green Tea Catechins

Dimethylhydrazine induced Wistar rats,
↓ACF, ↓tumor incidence, ↓cell proliferation

Xu et al

Green Tea
Phytic acid

Azoxymethane treated Fisher 344 rats,
↓ACF incidence

Challa et al

Tomato
Garlic

Azoxymethane treated Sprague Dawley rats,
↓cell proliferation, ↓apoptosis, ↓ACF

Sengupta et al

Fish oil, Corn oil,
Butyrate

Azoxymethane induced Sprague Dawley rats,
↑↓ACF, ↑p21, ↑↓apoptosis

Crim et al

Peppermint, Sage
Rosemary*

SW-480 colon cancer cells,
↓cell proliferation

Yi et al

Eicosapentaenoic acid
(EPA), Lycopene

HT29 colon cancer cells, ↓cell proliferation,
↓p-Akt, ↓p-mTOR, ↑Bax, ↑Fas

Tang et al

*This study used the Combination Index (CI) to determine synergism
(CI)
6

glutathione-S-transferase (Sengupta, Ghosh et al. 2003). Examination of the flavonoids
diosmin and hesperidin in combination revealed a significant decrease in ACF formation
in azoxymethane-treated rats (Tanaka, Makita et al. 1997). However, the combination
effect on ACF was not statistically stronger as compared to treatments with individual
agents.
The ApcMin/+ mouse model has been used frequently to determine
chemopreventive effects of dietary components against intestinal tumoigenesis. The
ApcMin/+ mouse model is a model for human familial adenomatous polyposis (FAP),
which is a hereditary disease characterized by the inactivation of one allele of the
adenomatous polyposis coli (APC) gene. Individuals diagnosed with FAP experience
multiple colonic polyps that without removal may eventually progress to colon cancer
(Rao and Reddy 2004). Although FAP only accounts for a small portion of diagnosed
cases of colorectal cancer, APC gene mutations are a common early occurrence in the
carcinogenesis process of the majority of colorectal tumors; therefore, use of the ApcMin/+
mouse model can offer insight into these early genetic events and aid in the development
of future chemopreventive agents (Powell, Zilz et al. 1992). The combination of
sulforaphane and dibenzoylmethane (a compound found in licorice) was investigated in
the ApcMin/+ mouse model (Shen, Khor et al. 2007). The combination treatment caused a
significant inhibition of tumor development as compared to the control. However, when
the chemopreventive effects of half-dose combinations of sulforaphane and
dibenzoylmethane were compared with those produced by full-dose combinations of
sulforaphane and dibenzoylmethane alone, no statistical difference was found; therefore,
further studies are required to examine a broad range of doses to determine the mode of
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interaction (additive or synergistic). A combined treatment of EGCG (a major green tea
polyphenol) and fish oil was used in the high fat diet of female ApcMin/+ mice to
determine if the combination decreased tumors more effectively than either agent alone
(Bose, Hao et al. 2007). The combination treatment for nine weeks resulted in a
significant decrease in the number of large tumors as compared to the control, a greater
effect than individual treatments. A combination treatment of EGCG and fish oil resulted
in tumors with decreased levels of prostaglandin E2 (PGE2), nuclear B-catechin, and
phosphorylated Akt, three potential procarcinogenic factors for colorectal cancer. The
combination of dietary components has also been found effective in inhibiting human
FAP. For example, in a case study of five FAP patients, all were found to have a
reduction in the number and size of adenomas following a six-month dietary treatment of
480 mg of curcumin and 20 mg of quercetin (a flavonol found in many fruits, vegetables,
and grains) in combination three times a day (Cruz-Correa, Shoskes et al. 2006),
highlighting the promising potential of dietary combination regimens for cancer
chemoprevention.

1.4.2

Fish Oil –Docosahexaenoic and Eiosapentaenoic Acid
Besides the aforementioned study on the combination of fish oil and EGCG in

ApcMin/+ mice, several other studies have focused on the combination of fish oil with
other dietary factors. In azoxymethane-treated rats, the dietary combination treatment of
fish oil plus butyrate for 11 weeks resulted in inhibition on colonic ACF formation
accompanied by increased apoptosis. In contrast, the combination of corn oil plus
butyrate led to increased ACF formation and had no effect on apoptosis (Crim, Sanders et
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al. 2008). Although both combinations increased the expression of p21, the fish oil plus
butyrate combination was chemopreventive, whereas the corn oil plus butyrate
combination was promotive of colon carcinogenesis. These findings highlight the
important role of interactions between dietary components and their effects on biological
outcomes. Studies evaluating fish oil components such as docosahexaenoic acid (DHA)
and eicosapentaenoic acid (EPA) offer clues to possible mechanisms involved in
combinations with fish oil. In human colon cancer cells and primary cultures of rat
colonic crypts, enhanced induction of apoptosis observed with the combination of
butyrate and DHA appeared to occur through a p53-independent mechanism that relied
on the upregulation of the mitochondrial Ca2+ -dependent pathway (Kolar, Barhoumi et
al. 2007). Lycopene and EPA in combination demonstrated a significant reduction of cell
proliferation in HT29 colon cancer cells (p<0.05), which was associated with inhibition
of the phosphatidylinositol 3-kinase/Akt signaling pathway (Tang, Cho et al. 2009).

1.4.3

Glucosinolates
One group of compounds under frequent investigation for their chemopreventive

effects against colon cancer are glucosinolates, in particular the glucosinolate breakdown
products such as sulforaphane, indole-3-carbinol, and their related derivatives. The main
source of glucosinolates in the human diet is cruciferous vegetables, some of which
include broccoli, cauliflower, Brussels sprouts, kale, and cabbage (Lund 2003; McGrath
and Spigelman 2008). Indole-3-carbinol and genistein (a soy isoflavone) in combination
were found to synergistically inhibit cell viability of HT29 human colon cancer cells
(CI<1) (Nakamura, Yogosawa et al. 2009). This inhibition was associated with
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inactivation of Akt, an important protein involved in the key signaling pathways known
to be overactive in colorectal cancer (Osaki, Oshimura et al. 2004). Synergistic
inhibitory effects on cell proliferation were also found in a combination study examining
the interaction between two glucosinolate products, 3,3'-diindolylmethane (DIM) and
sulforaphane, in a colorectal cancer cell line (Pappa, Strathmann et al. 2007). DIM, a
condensation product and dimer of indole-3-carbinol, is formed in the acidic environment
of the stomach and is the primary form of indole-3-carbinol absorbed in humans. In the
cell proliferation assay, a dose response effect was observed as lower concentrations of
the sulforaphane plus DIM combination became synergistic in its effects on decreasing
cell proliferation. The authors postulated the antagonistic interaction was due to the
induction of phase II enzyme expression by sulforaphane at low concentrations, which
increased metabolism of DIM and decreased its activities. Others have found less
pronounced effects on cell proliferation by the combination of glucosinolate products
such as indole-3-carbinol and 4-methoxyindole-3-carbinol in HCT116 colon cancer cells
(Kronbak, Duus et al. 2010). Glucosinolate products can be protective in the early stages
of carcinogenesis by diminishing the effects of genotoxic compounds (Bonnesen,
Eggleston et al. 2001). Sulforaphane and indolo[3,2b]carbazole (ICZ, a condensation
product of indole-3-carbinol) were studied in LS-174 colon cancer cells to determine
their effects on carcinogen/genotoxin exposure of benzo(a)pyrene or H2O2. In each case,
the combination treatment with sulforaphane and ICZ prior to carcinogen/genotoxin
exposure achieved greater DNA protection than either agent alone. It is notable that the
protection against DNA damage did not occur if the combination treatment followed
benzo(a)pyrene or H2O2 exposure. Multiple studies also suggest glucosinolate
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derivative combinations and other polyphenol combinations are more effective than their
individual components in halting initiation of the carcinogenesis process through the
induction of phase II enzymes (Nho and Jeffery 2004; Svehlikova, Wang et al. 2004;
Iwuchukwu, Tallarida et al. 2011; Saw, Cintron et al. 2011).

1.4.4

Multiple Component Interaction based on Food Source
One area of interest is the interaction of components within a specific food.

Butyrate and carnitine, both present in milk, have been found in combination to induce
apoptosis in colon cancer cells by increasing the expression of proapoptotic proteins Bax
and Bak and decreasing the expression of the COX-2 protein (Roy, Dionne et al. 2009).
Although the proapoptotic effects of butyrate and carnitine in combination were
significant as compared to the control, these enhanced effects were not significant when
compared to those exhibited by butyrate alone. Resveratrol and grape seed extract, both
found in grapes, have demonstrated synergistic effects in combination on the inhibition of
cancer cell proliferation and induction of apoptosis through a p53-dependent mechanism
in insulin-like growth factor-1 (IGF-1) stimulated HCT116 colon cancer cells
(Radhakrishnan, Reddivari et al. 2011). These findings may have important implications
for future chemopreventive strategies, as IGF-1 appears to play a pivotal role in the
development of obesity-driven colorectal cancer and p53 is characteristically intact in
colonic polyps, thereby offering a measureable outcome of treatment efficacy. The
combination of one agent with different agents may elicit distinct mechanisms of actions.
For example, when resveratrol was combined with a compound not found within grapes,
such as curcumin, the combination elicited a synergistic response that was p53-
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independent (Majumdar, Banerjee et al. 2009). This was different from the combination
of resveratrol and grape seed extract.

1.4.5

Whole Foods – Fractions and Extracts
The combination effects of dietary components on colon cancer have been

demonstrated in studies where the whole food and its fractions were compared. Total
cranberry extract was examined and separated into fractions of sugars, organic acids, total
polyphenols, proanthocyanidins, and anthocyanins to compare the efficacy of different
fractions in the inhibition of colon cancer cell growth (Seeram, Adams et al. 2004). The
greatest antiproliferative effect occurred with the total polyphenol fraction in HCT116
colon cancer cells, thereby suggesting a possible synergistic interaction among several
polyphenol components. In a similar study, pomegranate juice demonstrated greater
inhibition on HT-29 and HCT116 colon cancer cells than isolated individual polyphenol
components of pomegranate juice (Seeram, Adams et al. 2005). Upon further
examination, the pomegranate juice was found to have a significant effect on the
induction of apoptosis in HT-29 cells but no significant effect on apoptosis in the
HCT116 cell line. However, the individual polyphenol components of pomegranate juice
significantly increased apoptosis in HCT116 cells, suggesting different mechanisms are
responsible for the inhibitory effects of pomegranate juice in HT-29 colon cancer cells.
Whole food extracts have also been investigated for their combination effects. A
peppermint extract plus sage extract combination treatment synergistically inhibited the
growth of SW-480 colon cancer cells. However, rosemary extract and sage extract alone
was much stronger than peppermint extract in its inhibitory effects (Yi and Wetzstein
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2011). Notably, studies using crude food extracts in cell culture models have very
limited physiological relevance in terms of bioavailability and biotransformation of
different dietary components in humans. Nevertheless, these types of studies may
provide potential leads for further investigations using experimental models of better
physiological relevance.

1.4.6

Epigenetic Effects
Epigenetic events have been shown to play critical roles in regulating

carcinogenesis. Recent studies have examined epigenetic biomarkers to determine if the
combination of bioactive dietary components elicits enhanced epigenetic responses in
colorectal cancer models. Aberrant methylation frequently reported in colorectal cancer
was unaffected by the combination of isothiocyanates and selenium in Caco-2 and
HCT116 colon cancer cells (Barrera, Johnson et al. 2013). In contrast, a marked
reduction of abnormal methylation was indicated with decreased expression of DNA
methyltransferase-1 (DNMT1) following green-tea-plus-selenium combination treatment
in a rat colorectal cancer model (Hu, McIntosh et al. 2013). Interestingly, the same
combination also exhibited a greater induction of histone H3 acetylation than green tea or
selenium alone, an important finding as deacetylated histone H3 has been positively
associated with colorectal cancer development. Given the importance of epigenetic
events, the role of epigenetic mechanisms in the combination of dietary components in
colorectal cancer warrants further investigation.
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1.5

Prostate Cancer
As a cancer of high frequency, prostate cancer has been frequently investigated as

a target of combination treatments (Table 1.2). Effective modulation of the pathways
mediated by androgens (such as testosterone) and their products is an important strategy
for the inhibition of prostate carcinogenesis.

1.5.1

Soy Isoflavones and Soy Phytochemical Concentrate (SPC)
Both soy and selenium have shown the ability to individually work within these

androgen mediated pathways in animal models, thereby altering the course of disease.
Efficacy of soy isoflavones and selenium in combination was investigated in a Noble rat
model of hormone-induced prostate cancer (Legg, Tolman et al. 2008). The two oral
dosages of soy isoflavones were based on either the high consumption of soy among the
Asian population (often associated in epidemiological studies with a decreased risk of
prostate cancer) or the lower consumption of soy in the Western diet. The high
concentration combination treatment of selenium plus isoflavones was found to
significantly lower 5a-reductase activity as compared to the low concentration
combination treatment in the male Noble rats. The enzyme 5a-reductase is involved in
the reduction of testosterone to dihydrotestosterone (DHT), often elevated in prostate
cancer. Moreover, results from a complementary study in male Noble rats demonstrated
that combined dietary treatment with selenium and isoflavones produced stronger effects
in reducing prostate cancer risk factors than either agent individually, and timing of
dietary supplementation can greatly impact treatment efficacy (Tolman, Lephart et al.
2008). The combination of soy isoflavone genistein and resveratrol was investigated in
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SV-40 tag rats, a transgenic model of spontaneously developing prostate cancer (Harper,
Cook et al. 2009). The low-dose dietary combination regimen of genistein plus
resveratrol (both at 83 mg/kg diet) did not affect cancer outcome, whereas the high-dose
combination (both at 250 mg/kg diet) was effective in reducing the overall occurrence of
prostate cancer. However, there was no evidence of a synergistic interaction between
genistein and resveratrol that may increase chemopreventive effects of the individual
agents. The expression of the androgen receptor (AR) protein was significantly increased
by the single treatment of resveratrol, but the high-dose combination of genistein and
resveratrol exhibited no increase in the expression of the AR protein. These findings
suggest a potential opposing mechanism exists between genistein and resveratrol in
regulating the expression of the AR protein. Cancer chemopreventive effects on
androgens and their products have also been observed in the combination of soy and tea.
A soy phytochemical concentrate (SPC) was used in combination with tea infusions of
black or green tea as the sole source of drinking water in severe combined
immunodeficiency (SCID) male mice inoculated with LNCaP human prostate cancer
cells (Zhou, Yu et al. 2003). The SPC plus tea combinations were more effective in the
reduction of tumor weight and metastasis to lymph nodes than individual treatments. Of
particular interest, green tea alone elevated serum levels of DHT, whereas the SPC plus
green tea combination significantly reduced serum levels of DHT, thereby suggesting a
modulatory role of the androgen system as one of the mechanisms responsible for the
combinatorial anticarcinogenic effects between SPC and green tea.
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Table 1.2 Studies examining the effects of the combination of dietary bioactive
components in prostate cancer
Combination
Model System
References
Treatment
Mechanism/Effect
Genistein, Quercetin,
Biochanin A

PC-3, LNCaP, DU-145 prostate cancer cells,
Kumar et al
↑bax, ↑caspase-3, ↓bcl-2, ↑ER-β, ↑p-JNK, ↓pERK, ↓PCNA, ↓cell proliferation↑apoptosis

Genistein
Selenium

PC-3 and LNCaP prostate cancer cells,
↓MMP-2, ↑apoptosis, ↓cell growth

Kumi-Diaka
et al

Resveratrol
β-sitosterol

PC-3 prostate cancer cells, ↓ROS,
↓prostaglandin, ↓cell growth

Awad et al

Epigallocatechin gallate, CWR22Rv1 prostate cancer cells, ↑p53,
Genistein, Quercetin
↓cell proliferation, ↑NQO2, ↑AR

Hsieh et al

Quercetin
Epigallocatechin gallate

CD44+ and CD133+ cancer stem cells
isolated from PC-3, LNCaP and prostate
cancer tumors
↑apoptosis, ↓cell proliferation,↓cell viability,
↓colony formation, ↓migration, ↓invasion

Tang et al

Thearubigin
Genistein

PC-3 prostate cancer cells, ↓cell growth,
↑G2/M phase cell cycle arrest

Sakamoto et al

Pomegranate juice
polyphenols,seed oil,
peel polyphenols*

DU 145 and PC-3 prostate cancer cells,
↓cell proliferation, ↓PLA2, ↓invasion

Lansky et al

Ellagic acid
Urolithin A*

PC-3 prostate cancer cells,
↓cell proliferation

Vicinanza et
al

Ginger Biophenolics*

PC-3 prostate cancer cells,
↓cell proliferation

Brahmbhatt
et al

Daidzein
Genistein

LNCap and C4-2B prostate cancer cells,
↓cell proliferation, ↑apoptosis

Dong et al

Whole soy extract
Daidzein, Genistein

PC-3 and LnCap prostate cancer cells,
↑apoptosis, ↑ sub-G1 cell population

Hsu et al
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Table 1.2 Continued
Combination
Treatment

Model System
Mechanism/Effect

References

Isoflavones
Selenium

Noble rats hormone induced prostate
Cancer, 5alpha-reductase activity

Legg et al

Selenium
Isoflavones

Noble rats hormone induced prostate cancer,
↓IGF-1, ↑leptin, ↓weight

Tolman et al

Soy phytochemical
extract(SPC), green
and black tea

SCID mice, ↓dihydrotestosterone,
↓tumor weight, ↓metastasis to lymph nodes

Zhou et al

Green Tea
Soy

Noble rats implanted with estradiol and
testosterone, ↓p50, ↓IL-6, ↓IL-1β, ↓TNFalpha, ↓infiltrating inflammatory cells

Hsu et al

Tomato
Broccoli

Copenhagen rats Dunning R3327-H,
↓tumor weight, ↓tumor growth

Canene-Adams
et al

Tomato Powder
Soy Germ

Mouse prostate TRAMP model,
No significant effects as compared to
individual components

Zuniga et al

Lycopene, Vitamin E,
Selenium

Copenhagen rats Dunning R3327-H,
No significant effects as compared to
individual components

Lindshield
et al

Lycopene, Vitamin E
Selenium

Lady transgenic mice model,
↓PCNA, ↑apoptosis, ↓prostate cancer
incidence

Venkateswaran
et al

Lycopene
Soy Isoflavones

Phase II clinical trial men w/prostate cancer,
Opposing effects on PSA stabilization

Vaishampayan
et al

Lycopene
Lutein

AT3 rat prostate cancer cells,
No significant effects as compared to
individual components

Gunasekera
et al

Genistein
Resveratrol

SV-40 Tag rats,
opposing effects on AR receptor
↓cell proliferation

Harper et al

*This study used the Combination Index (CI) to determine synergism
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A substantial amount of research suggests soy isoflavones exhibit the ability to
modulate multiple pathways involved in the pathology of prostate cancer. Genistein was
shown to demonstrate strong combinatorial effects with different agents in the
downregulation of cell proliferation and induction of apoptosis in both hormonedependent and –independent prostate cancer cell lines. For example, genistein and
selenium in combination significantly decreased cell proliferation and increased
apoptosis and caspase-3 activity as compared to individual treatments in PC-3 (hormoneindependent) and LNCaP (hormone-dependent) prostate cancer cells, thus implying the
effects of the genistein plus selenium combination are not hormone dependent within
these cell lines (Kumi-Diaka, Merchant et al. 2010). The interaction of genistein plus
quercetin plus biochanin A was studied in LNCaP, DU-145, and PC-3 prostate cancer
cells (Kumar, Verma et al. 2011). The triple combination was found to be more
efficacious in the inhibition of cell proliferation in both estrogen receptor (ER)-dependent
and –independent pathways than each component alone. Further mechanistic
investigation in PC-3 cells demonstrated that the combination treatment of genistein plus
quercetin plus biochanin A induced apoptosis, increased the activation of caspase-3, and
up-regulated the expression of the ER-B gene (a gene important for the regulation of
tumor repressor activity in prostate cancer). Indeed, the triple combination was more
effective than individual or double combinations in modulating some of the key
regulatory proteins, including BAX, bcl-2, pJNK, pERK-1/2, and PCNA in PC-3 prostate
cancer cells.
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1.5.2

Tea Components
Other studies point to the increased anticarcinogenic effects that occur when

quercetin or genistein are combined with tea components. The combination of quercetin
and EGCG was examined in prostate cancer stem cells and was found to produce
pronounced inhibitory effects on cell viability, colony formation, metastasis, and cell
invasion (Tang, Singh et al. 2010). Likewise, combined treatment of thearubigin (a tea
component) plus genistein in PC-3 prostate cancer cells resulted in a substantial decrease
in cell growth, and this inhibitory effect was stronger than that produced by thearubigin
or genistein alone (Sakamoto 2000). Different mechanisms of action by thearubigin and
genistein in the regulation of the G2/M cell cycle phase were proposed to be responsible
for the observed suppression of cell proliferation. A triple combination of genistein plus
EGCG plus quercetin was found to produce an enhanced inhibition of cell proliferation in
CWR22Rv1 prostate cancer cells, a model reflective of the transition from androgen
dependence to hormone refractory prostate cancer (Hsieh and Wu 2009). Although the
known mechanisms of the individual components within a combination can complement
each other and result in a potentiated effect, a new mechanism that is not evident to the
individual components within the combination can also be revealed from the combination
treatment. For example, in the Noble rat model of prostate carcinogenesis, the
combination of soy and green tea produced an anti-inflammatory interaction that is not
apparent for soy or green tea individually (Hsu, Bruno et al. 2011).
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1.5.3

Multiple Component Interaction within the Same Food
The results from studies where components from the same food are subjected to

investigation must be interpreted carefully. For example, fermented pomegranate juice
polyphenols, pomegranate peel polyphenols, and the pomegranate seed oil were analyzed
to determine their effects individually and in combination on the proliferation of DU-145
prostate cancer cells (Lansky, Jiang et al. 2005). It was found that both the oil plus juice
and peel plus juice combinations exhibited synergistic effects on diminishing
proliferation of the cancer cells. However, the pomengranate juice and peel contained
many of the same compounds. Therefore, the combination effects produced by the peel
plus juice combination could be merely a dose response rather than a meaningful
interaction. However, research findings continue to show that multiple dietary
components from the same food in combination cause greater anticarcinogenic effects
than individual components. For example, the antiproliferative effects of the
pomegranate metabolites ellagic acid and urolithin A in combination were determined in
PC-3 prostate cancer cells, and the combined treatment was found to result in a marked
synergistic decrease in cell proliferation (Vicinanza, Zhang et al. 2013). Similarly, the
combination of ginger biphenolic compounds exhibits a strong synergism of
antiproliferative effects in PC-3 prostate cancer cells (Brahmbhatt, Gundala et al. 2013).
Furthermore, combined treatment of soy isoflavones (genistein plus daidzein) was found
to be more effective in the induction of apoptosis and suppression of proliferation than
individual isoflavones in a prostate cancer progression model (Dong, Xu et al. 2013).
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1.5.4

Whole Foods
Recent studies examining whole foods have revealed enhanced anticarcinogenic

effects that are attributed to the combination of multiple components present in the whole
food or several foods combined (Basu and Imrhan 2007). Some studies have reported
inhibition of prostate carcinogenesis by lycopene, the bioactive compound found in
tomatoes (Siler, Barella et al. 2004). However, other studies have found that the whole
tomato was more efficacious. Indeed, whole tomato powder at 10% of the diet
significantly decreased tumor weight in a Dunning R3327-H prostate adenocarcinoma
model, whereas lycopene as part of the diet at a very high dose did not exhibit any
significant effect in decreasing tumor weight. Whole broccoli powder at 10% of the diet
significantly decreased tumor weight. Most interestingly, the combination of whole
tomato powder plus broccoli powder had an even greater effect on diminished tumor
weight (Canene-Adams, Lindshield et al. 2007). In another study, the combination of
whole tomato powder and soy germ was effective in diminishing prostate cancer
incidence in the mouse prostate TRAMP model, but the inhibitory effects were not
significantly different from those produced by each individual treatment (Zuniga, Clinton
et al. 2013). Notably, whole soy extract significantly increased apoptosis in LnCap and
PC-3 prostate cancer cells as compared to single treatment of individual soy isoflavones,
genistein and daidzein.

1.5.5

Clinical Outcome vs Preclinical Findings
Recent prostate cancer clinical trials utilizing combinations warrant caution when

extrapolating preclinical findings to a human population. A Phase II clinical trial
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investigated the consumption of lycopene alone and in combination with soy isoflavones
to determine their efficacy in the modulation of rising serum prostate-specific antigen
(PSA) levels of 71 men with prostate cancer (Vaishampayan, Hussain et al. 2007).
Treatment groups were randomized with 38 subjects receiving 15 mg of lycopene alone
and 33 subjects receiving 15 mg of lycopene plus 40 mg of a soy isoflavone mixture
twice daily for six months. Surprisingly, PSA stabilization for a minimum of three
months occurred for 95% of the lycopene group but occurred for only 67% of the
combination group. These results may suggest an antagonistic effect between lycopene
and soy isoflavone mixtures in stablilizing PSA. The Selenium and Vitamin E Cancer
and Prevention Trial (SELECT) examined the efficacy of the combination of selenium
and vitamin E for prostate cancer prevention (Klein, Thompson et al. 2011). Although
preclinical studies of prostate cancer have reported anticarcinogenic effects of vitamin E
and selenium alone and in combination, the clinical outcome has proven to be quite
different as vitamin E was found to increase the occurrence of prostate cancer when used
alone and to a lesser degree in combination with selenium (Venkateswaran, Fleshner et
al. 2004; Reagan-Shaw, Nihal et al. 2008). In agreement with these clinical findings, an
animal study using the Lady transgenic model indicated that the combination of vitamin
E and selenium was not chemopreventive but rather causative of an increased occurrence
of prostate cancer (Venkateswaran, Klotz et al. 2009). Interestingly, when lycopene was
added to the combination of vitamin E and selenium, the results were quite different such
that the triple combination treatment significantly decreased the occurrence of prostate
cancer in mice. However, the same triple combination of vitamin E plus selenium plus
lycopene showed no inhibitory effect in male Copenhagen rats transplanted with
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androgen-dependent Dunning R3327-H rat prostate adenocarcinomas (Lindshield, Ford
et al. 2010). These conflicting results exemplify how an accumulation of cellular and
animal findings is not always indicative of clinical outcome.

1.6

Breast Cancer
Table 1.3 summarizes the major studies on breast cancer and the

chemopreventive effects of combination treatments with dietary components.
Epidemiological studies suggest certain foods commonly consumed in the Asian diet may
be protective against the development of breast cancer (Butler, Wu et al. 2010).

1.6.1

Soy, Tea and their Components
Two foods that encompass a prominent position within the Asian diet that have

been explored for their inhibitory effects on breast cancer are soy and tea. In one such
study, a soy phytochemical concentrate (SPC) was used in combination with either green
tea or black tea infusions as part of the diets of female SCID mice bearing implanted
tumors of MCF-7 breast cancer cells (Zhou, Yu et al. 2004). The soy concentrate plus
green tea combination was found to be more effective in tumor weight reduction as
compared to the control. Potential mechanisms underlying the actions of the combination
treatment were proposed to include downregulation of ER-a, reduction of serum IGF-1
levels, and inhibition of angiogenesis. Another study reinforced the effects of the
combination on IGF-1and ER-a by showing a substantial reduction in serum IGF-1 and
estrogen concentration following a soy concentrate plus green tea combination treatment
in FVB/N mice (Zhou, Li et al. 2007). When EGCG was added to the resveratrol plus y-
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tocotrienol combination, it did not result in any increase in the inhibition of proliferation
of MCF-7 breast cancer cells (Hsieh and Wu 2008). However, a pronounced increase
was noted in the induction of quinone reductase NQO1 (a phase II enzyme) following
exposure to the triple combination treatment of EGCG plus resveratrol plus y-tocotrienol.
Evaluation of the combination effects on the Rb/E2F protein complex, an important
regulatory complex of the cell cycle progression, revealed greater inhibition of the Rb
protein by each of the two component combinations tested than by individual treatment
alone. Surprisingly, a diminished inhibitory effect on the Rb protein occurred following
the exposure to the triple combination of EGCG plus resveratrol plus y-tocotrienol in the
breast cancer cells. These findings highlighted the complexity that is involved when
combining multiple components for cancer inhibition and underscored the need for more
combination studies to evaluate the variable interactions that can exist between different
dietary bioactive components.
Soy isoflavones have been investigated for their use in combination treatments to
determine their ability as phytoestrogens to suppress breast cancer through the regulation
of the ERs and estrogen-responsive genes (Willard and Frawley 1998). The effects of
genistein and indole-3-carbinol in combination were studied on the expression of BRCA1
and BRCA2 in estrogen-responsive MCF-7 breast cancer cells (Fan, Meng et al. 2006).
Both BRCA1 and BRCA2 have been identified as tumor suppressor genes for hormoneresponsive breast cancer, and the absence or decrease in the expression of BRCA1 has
been observed in a significant proportion of sporadic breast cancers, suggesting its
protective role against breast carcinogenesis. Combination treatment of genistein and

24

Table 1.3 Studies examining the effects of the combination of dietary bioactive
components on breast cancer
Combination
Model System
References
Treatment
Mechanism/Effect
Eicosapentaenoic acid
Genistein*

MDA-MB-231 and MCF-7 breast cancer
cells, ↓cell proliferation

Nakagawa
et al

Epigallocatechin,
Resveratrol, γtocotrienol

MCF-7 breast cancer cells,
↑NQO1, opposing effects on Rb/E2F protein

Hsieh et al

Indole-3-carbinol
genistein

MCF-7 breast cancer cells,
↑BRCA1, ↑BRCA2

Fan et al

Genistein,3,3'diindolylmethane
(DIM)

MDA-MB-231 breast cancer cells,
↓CXCR4, ↓chemoinvasion

Hsu et al

Pomegranate extract
Genistein

MCF-7 breast cancer cells,
↓cell growth↑apoptosis

Jeune et al

Curcumin
Genistein

MCF-7 breast cancer cells,
↓cell proliferation

Verma et al

Quercetin 3-β-Dglucoside
(Q3G), Apple extract*

MCF-7 breast cancer cells, ↑Q3G
stabilization, ↑bioavailability, ↓cell
proliferation

Yang et al

Docosahexaenoic acid
Curcumin*

SK-BR-3 breast cancer cells, ↑bioavailability,
↓cell proliferation, ↑p-53, ↑PPARγ

Altenburg
et al

Soy phytochemical
concentrate (SPC),
Black tea, Green tea

SCID mice model of MCF-7 tumor growth,
↓tumor weight, ↓estrogen receptor-α,
↓serum insulin-like growth factor (IGF)-I

Zhou et al

Soy, Green Tea, Black
Tea components

FVB/N mice, ↓serum estrogen,
↓serum insulin-like growth factor (IGF-I)

Zhou et al

Diallyl sulfide,
ellagic acid, Semethylselenocysteine,
Selenomethionine,
Quercetin

Dimethylbenz[a]anthracene (DMBA) treated
Sprague-Dawley,
↓tumor incidence

Ip et al
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Table 1.3 Continued
Combination
Treatment

Model System
Mechanism/Effect

References

Flaxseed
Soy protein

Ovariectomized athymic nude mice with
MCF-7 tumor, ↓tumor growth, ↓pMAPK,
↓IGF-1Rβ

Power et al

Soy protein
Fish oil

Sprague-Dawley rats,
↑apoptosis

Kramer et al

Genistein
Daidzein

Nude mice model of green fluorescent
protein tagged (GFP) MDA-MB-435 tumors,
↑metastasis to lung, liver, heart, kidney,
Bones

MartinezMontemayor
et al

Flaxseed
Soy protein

Ovariectomized athymic nude mice with
MCF-7 tumor, ↓cell proliferation, ↓tumor
growth, ↑apoptosis

Saarinen et al

*This study used the Combination Index (CI) to determine synergism

indole-3-carbinol in MCF-7 breast cancer cells resulted in a significant increase of the
levels of BRCA1 and BRCA2 protein, and these effects were greater than those produced
by genistein or indole-3-carbinol treatment alsone. These pronounced chemopreventive
effects were speculated to be initiated by the activation of the endoplasmic reticulum
stress response signaling pathway, thereby leading to the expression of downstream target
genes by genistein and DIM, a metabolite of indole-3-carbinol. Interestingly, the
combination treatment of genistein and DIM also demonstrated anticarcinogenic effects
in estrogen-negative MDA-MB-231 breast cancer cells(Hsu, Chen et al. 2009). Genistein
and DIM in combination were efficacious in inhibiting the chemoinvasion of cells toward
CXCL12, a chemokine receptor and ligand necessary for the metastasis of breast cancer.
ER-positive MCF-7 breast cancer cells were found to be highly responsive to the
26

combination treatment of genistein plus pomegranate extract that led to stronger
inhibition of cell growth and induction of apoptosis as compared to individual
components (Jeune, Kumi-Diaka et al. 2005). Genistein and curcumin in combination
exhibited a strong inhibitory effect on cell proliferation in MCF-7 breast cancer cells
following 17-B estradiol and estrogenic pesticide exposure (Verma, Salamone et al.
1997). The combination treatment of genistein plus EPA has been reported to
synergistically inhibit the growth of both MCF-7 and MDA-MB-231 breast cancer
cells(Nakagawa, Yamamoto et al. 2000). The MCF-7 cells showed a greater sensitivity
to the combination of genistein and EPA than the MDA-MB-231 cells. This variation in
response appeared to be independent of ER status, thereby suggesting different
mechanisms at work in ER-positive and ER-negative breast cancer cells.

1.6.2

Increased Bioavailability and Cellular Uptake
Many of the synergistic effects observed in the combination treatments have been

attributed to complementary mechanisms, some of which suggest increased
bioavailability as a possible mechanism for enhanced anticarcinogenic effects. Apple
extract and quercetin 3-B-glucoside (Q3G) in combination synergistically decreased cell
proliferation of MCF-7 breast cancer cells (Yang and Liu 2009). The synergistic
antiproliferative effects of the combination were speculated to entail mechanisms
associated with stabilization and increased bioavailability of Q3G. These findings are of
particular interest in the use of compounds with poor bioavailability such as curcumin, as
only a very small fraction of ingested curcumin are absorbed in humans; indeed, only a
low micromolar concentration is present in the bloodstream from the ingestion of several
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grams of curcumin (Garcea, Berry et al. 2005). For example, curcumin in combination
with DHA was found to synergistically inhibit cell proliferation of ER-negative HER-2
positive SK-BR-3 breast cancer cells (Altenburg, Bieberich et al. 2011). A combination
treatment of curcumin plus DHA in SK-BR-3 cells increased phosphorylation of p53 and
expression of PPARy more than each compound alone. In the presence of DHA, the
cellular uptake of curcumin in SK-BR-3 cells was greatly increased, perhaps through
changes in the lipid membrane by DHA. This increased cellular uptake of curcumin
within the SK-BR-3 cells could be a key mechanism for the enhanced anticarcinogenic
effects of the curcumin plus DHA combination. Indeed, this combination could have
important clinical implications. It utilized a targeted treatment strategy to offer enhanced
bioavailability of anticancer agents within a particular phenotype of cancer cells, which
in turn led to a greater anticancer efficacy.

1.6.3

Combinatorial Mechanisms Offset Negative Effects
Dietary bioactive components may work as chemopreventive agents at different

stages of carcinogenesis, and the combination of these components may produce stronger
inhibition on carcinogenesis. Three different combination treatments were studied in a
dimethylbenz[a]anthracene (DMBA)-induced mammary tumor model in Sprague-Dawley
rats, including diallyl sulfide plus Se-methylselenocysteine, ellagic acid plus
selenomethionine, and diallyl sulfide plus quercetin (Ip and Ganther 1991). Selection
criteria for the combination were based on the inclusion of one compound effective prior
to carcinogen exposure and another compound effective post initiation; the individual
compound was given either before or after DMBA exposure, based on the mode of
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action. Each of the three combinations achieved a greater degree of tumor suppression
than individual compounds. Indeed, only the combination treatment significantly
decreased both tumo incidence and number as compared to the control. The combination
of flaxseed and soy, which was based on the premise that flaxseed may modulate the
effects of soy to offset the negative effects attributed to the ingestion of soy by at-risk
populations, provides a recent example of a complementary combinatorial mechanism of
dietary components (Power and Thompson 2007). Although soy isoflavones have been
touted for their many health benefits, accumulating o data point to the potential adverse
effects of these compounds for postmenopausal women and those with existing breast
cancer (Martinez-Montemayor, Otero-Franqui et al. 2010). Flaxseed in combination with
soy protein has been shown to reduce the tumor-stimulating effects of soy in
ovariectomized athymic mice (Saarinen, Power et al. 2006; Power, Chen et al. 2008).
Therefore, this combinatorial interaction could be beneficial in allowing women at
increased risk of breast cancer to ingest soy with flaxseed, thereby obtaining the health
benefits of soy without the added risk. Along this line of findings, a complementary role
of fish oil was identified in another study when it was combined with soy protein and
found to offset the overexpression of ER-a, thus diminishing the potential negative
tumorigenic effects of soy protein (Kramer, Johnson et al. 2009).

1.7

Lung Cancer
Lung cancer is the most commonly occurring cancer; however, few combination

studies have been conducted to investigate multiple dietary bioactive components and
their influence on lung carcinogenesis. Tea components in combination with other
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compounds have been studied and have exhibited enhanced chemopreventive effects.
Lung cancer cell lines expressing wild-type p53 were found to be more sensitive than cell
lines not expressing p53 to the combination treatment of EGCG plus luteolin (Amin,
Wang et al. 2010). Notably, the combination of EGCG plus luteolin induced extensive
apoptosis in lung cancer cells expressing wild-type p53, and these effects were stronger
than those produced by EGCG or luteolin alone. Indeed, knockdown of p53 expression
in lung cancer cells resulted in a great inhibition of apoptosis induced by the combination
treatment, thereby suggesting a p53-dependent mechanism for inducing apoptosis by the
combination. Importantly, the efficacy of the EGCG plus luteolin combination was
further confirmed in vivo in a xenograft tumor model in nude mice that showed a
significant inhibition of tumor growth by the combination treatment. Another tea
polyphenol, (-)-epicatechin (EC), was combined with curcumin in the treatment of PC-9
and A549 lung cancer cells (Saha, Kuzuhara et al. 2010). EC alone had no suppressive
effect on either cell line in the test concentrations. However, EC in combination with
curcumin exhibited approximately four times greater suppression of the growth of PC-9
cancer cells than curcumin alone. Similar results were observed in A549 cells. The
enhanced anticancer effects were ascribed to the modulation of MAPK signaling by the
combination treatment. Theaflavin-3-3'-digallate plus ascorbic acid and EGCG plus
ascorbic acid, both combination treatments using tea polyphenols, were found to exhibit
synergism in the inhibition of cell proliferation of SPC-A-1 lung cancer cells (Li, Wu et
al. 2010). Cell cycle arrest at G0/G1 phase is responsible for the synergistic effects.
Chemopreventive effects of green tea polyphenols have been demonstrated in many
studies, but these beneficial effects were limited due to poor bioavailability of tea
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polyphenols. One factor contributing to the poor bioavailability of tea polyphenols is that
they undergo extensive biotransformation such as methylation, which may decrease their
bioactivities. Interestingly, in the presence of quercetin, methylation of EGCG was
significantly reduced in cancer cells. Consequently, the combination of quercetin and
EGCG produced enhanced inhibitory effects on proliferation of lung cancer cells (Wang,
Heber et al. 2012). To confirm these findings in vivo, SCID mice were given brewed
green tea and quercetin alone or in combination for two weeks. In agreement with the in
vitro results, the quercetin treatment greatly reduced the amount of methylated EGCG in
the lung and kidney of mice. Indole-3-carbinol and silibinin, a flavonoid of milk thistle,
have been used in combination to inhibit lung cancer, both in vitro and in vivo (Dagne,
Melkamu et al. 2011). Low concentrations of indole-3-carbinol and silibinin in
combination exhibited much stronger inhibitory effects on lung cancer cells than those
produced by the individual compounds at higher concentrations. The inhibitory effects
by the combination were associated with inactivation of Akt and ERK. These findings
were confirmed in A/J mice where combination treatment of indole-3-carbinol and
silibinin significantly inhibited lung carcinogenesis and downregulated Akt and ERK
pathways. Moreover, the effects produced by the combination treatment were stronger
than those of individual compounds.

1.8

Other Cancers
As discussed above, combination treatments with dietary bioactive components

have demonstrated enhanced anticarcinogenic effects in colon, prostate, breast, and lung
cancer models, but few studies have examined the efficacy of these combinations in less
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frequently occurring cancers. Some of the key dietary components used in
aforementioned combination studies appear to exhibit similar chemopreventive actions in
other less common cancers.

1.8.1

Curcumin, Soy Isoflavone and Tea Components
Curcumin in combination with carnosic acid displayed a strong synergism in

inhibiting acute myeloid leukemia cells accompanied by enhanced activation of apoptotic
pathways (Pesakhov, Khanin et al. 2010). Combination treatment of curcumin plus
isoflavone synergistically inhibited cell growth of BxPC-3 pancreatic cancer cells (Wang,
Desmoulin et al. 2008). Furthermore, the combination treatment produced stronger
inhibition on Notch 1 and NF-kB-mediated pathways than that attained by either
compound alone.
EGCG in combination with curcumin showed pronounced synergism in an oral
cancer cell model and exhibited underlying mechanisms involving G1 and G2 cell cycle
arrest. The combination treatment of tea catechins EC plus EGCG induced apoptosis
more than twofold that of the individual compounds in gastric carcinoma cells,
suggesting a synergistic interaction as EC alone had almost no effect on apoptosis (Horie,
Hirabayashi et al. 2005). Additionally, the combination of black tea polyphenol and
resveratrol caused an enhanced inhibition of tumor incidence, tumor size, and tumor
number in a two-stage mouse skin carcinogenesis model.
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1.8.2

Resveratrol and Glucosinolates
Resveratrol was studied in combination with polyphenolic compounds ellagic

acid and quercetin in MOLT-4 leukemia cells (Mertens-Talcott and Percival 2005). The
resveratrol plus quercetin combination resulted in a greater-than-additive effect in
inducing apoptosis and less-than-additive effect in decreasing cell proliferation; the
resveratrol plus ellagic acid combination, however, produced a greater-than-additive
effect in both inducing apoptosis and decreasing cell proliferation. Examination of
resveratrol in combination with indole-3 carbinol in SK-OV-3 ovarian cancer cells
revealed a significant increase of G1 and G2 arrest by the combination treatment (Raj,
Abd Elmageed et al. 2008). Enhanced proapoptotic effects were produced by the
combination of resveratrol with sulforaphane in human U251 glioma brain cancer cells,
which was accompanied by a pronounced decrease of Akt activation and an increase of
caspase-3 activation.
In PANC-1 pancreatic cancer cells, sulforaphane plus benzyl isothiocyanate
combination treatments produced a potent inhibition of cell viability that was associated
with inactivation of STAT3 and increase of apoptosis (Hutzen, Willis et al. 2009).
Substantial reductions in the growth of mouse melanoma (B16F10) cells in vitro and in
vivo with diminished MMP-9 expression were observed following a combination
treatment of sulforaphane plus quercetin. The combination treatment showed strong
inhibitory effects on melanoma both in vitro and in vivo, and these effects were stronger
than those of each individual treatment (Pradhan, Mishra et al. 2010).
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1.8.3

Garlic Components
Combinations of S-allylcysteine (an organosulfur component in garlic) and

lycopene in vivo produced a greater induction of apoptosis in gastric cancer of Wistar rats
in comparison to individual treatments (Velmurugan, Mani et al. 2005). Another garlic
compound, diallyl sulfide, in combination with pomegranate fruit extract demonstrated a
marked inhibition of a two-stage skin carcinogenesis in a mouse model (George, Singh et
al. 2011). Combined treatment led to a significant regression in tumor volume; however,
no effect was found on tumor number.

1.9

Concluding Remarks and Future Directions
Accumulating studies have demonstrated the potential of combination regimens

with dietary bioactive components as a promising strategy for cancer chemoprevention.
However, much remains to be explored for establishing a better understanding of the
mechanisms of action of different dietary components in combination. Important
information on the efficacy of combination regimens in humans is currently lacking.
Additionally, more retrospective and prospective epidemiological studies should be
conducted to determine the combinatorial effects of dietary bioactive components in
inhibiting carcinogenesis of different organs. The promising leads identified in the
epidemiological studies can be further validated in animal carcinogenesis models,
especially for whole foods and their crude fractions; in vitro models such as cell culture
assays offer very limited ability to account for the bioavailability and biotransformation
of dietary components in humans. For example, results obtained with dietary compounds
at concentrations too high to be achievable in human blood or specific tissues have a low

34

probability of being realized in humans. Ultimately, randomized, double-blind, placebocontrolled trials are needed to clearly demonstrate the efficacy of the combinations of
dietary bioactive components.
Currently, only a small fraction of existing studies employ combination indexbased statistical methods to design combination studies and to determine the modes of
interaction among different dietary bioactive components (Tables 1.1-1.3). This is far
from adequate to provide important information that can be conveniently compared and
analyzed to establish efficacy and mechanisms of action of specific combination
regimens. Therefore, standardization of protocols for combination studies is essential.
Use of the same statistical method such as the combination index-based method provides
a consistent interpretation of interactions allowing meaningful cross-examination of
results from different laboratories.
Although numerous studies show that complementary mechanisms of individual
dietary components can result in enhanced anticarcinogenic effects when used in
combination, caution is warranted as certain dietary component combinations can be
antagonistic with diminished anti-cancer effects and in some instances can even act as a
promoter of carcinogenesis. In these cases, it is critical to understand how these
components interact within the particular combinations so that recommendations can be
made to avoid potential adverse effects. These types of recommendations are of
particular importance to consumers taking dietary supplements, as many bioactive
components are already combined in dietary supplement products, which is further
complicated by consumers’ tendency to consume multiple supplements at the same time.
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CHAPTER 2
NON-SYNERGISTIC ANTI-PROLIFERATIVE EFFECTS OF SELECTED
FLAVONOIDS AND FLAVONOID METABOLITE IN COMBINATION FOR
CHEMOPREVENTION OF COLORECTAL CANCER

2.1

Abstract

Flavonoids and their metabolites have been highlighted for their anti-carcinogenic and
anti-inflammatory properties in colorectal cancer animal and cellular models, however
many of their effects in combination have yet to be explored. Herein, we examine the
anti-proliferative effects of two structurally similar flavones, luteolin or apigenin
(differing only in hydroxylation at 3' of the B-ring) in combination with 3',4'didemethylnobiletin (DDMN), a primary metabolite of nobiletin in the mouse. The
individual anti-proliferative order of potency in HCT116 colon cancer cells was found to
be apigenin > luteolin > DDMN. Our findings suggest the methoxylated A-ring on the
DDMN structure is associated with a lower anti-proliferative effect than observed in
luteolin which differs structurally only in the A-ring containing a hydroxyl group at the 5and 7-position with no methoxyl group. Moreover, results indicate that apigenin and
DDMN are additive when combined in a 1:1 ratio in HCT116 colon cancer cells at 1.5, 3,
4.5, 6 and 7.5 µM with no apparent interaction; whereas luteolin in combination with
DDMN in a 1:1 ratio at 1.5, 3, 4.5, 6 and 7.5 µM exhibits an antagonistic response with
diminished anti-proliferative effects in a dose dependent manner. Therefore, these
findings suggest the presence of the 3' hydroxyl group on the B-ring of luteolin is
associated with decreased inhibition of cellular growth, as compared to apigenin,
following combination treatment with DDMN in HCT116 colon cancer cells. Taken
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together, our research demonstrates for the first time the antagonistic anti-proliferative
effects of luteolin and DDMN in combination in HCT116 colon cancer cells.

2.2

Keywords

Flavonoids, diet-based strategies, combination, cancer chemoprevention, colorectal
cancer, flavonoid metabolites, anti-proliferative, antagonistic, additive, non-synergistic,
flavones, secondary plant metabolites, interaction, flavonoid structure

2.3

Abbreviations

DDMN: 3',4'-didemethylnobiletin; ACF: aberrant crypt foci; PMF: polymethoxyflavone;
AOM: azoxymethane; DMH: dimethylhydrazine

2.4

Introduction
Colorectal cancer is the third most commonly occurring cancer in the United

States currently diagnosed in both men and women (Siegel, Miller et al. 2017). Rates of
incidence and mortality have continued to decline in the 50-65+ age group; some of these
changes have been attributed to decreased consumption of red meat, increased use of
daily aspirin and the avoidance of smoking. Advances in colon cancer prognosis have
also been made in recent years through early diagnosis. However, troubling statistics
indicate that incidence and mortality rates have been increasing in younger adults age
<50 by 22% (2000 to 2013) and 13% (2000-2014) respectively; more research is needed
to better understand the mechanisms involved and to identify efficacious treatments that
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can be used for extended periods of time with no toxicity, to prevent or halt the
carcinogenic process.
Diet-based strategies for the chemoprevention of colorectal cancer are of
particular interest due to their low toxicity and anti-cancer effects. In addition, dietary
components come into direct contact with the colon, avoiding many of the bioavailability
challenges often encountered in other cancers with diminished delivery of the active
components into the bloodstream and to the target organ of interest. Therefore, the
dietary components direct contact with the colon is likely to result in more of the parent
compound and its active metabolites successfully reaching the colon for their therapeutic
effects (Sak 2014; Ullah, Bhat et al. 2016).
Flavonoids are secondary plant metabolites, a group of polyphenolic compounds
with anti-carcinogenic, anti-inflammatory and antioxidant properties (Pan, Lai et al.
2010; Gonzalez, Ballester et al. 2011). An abundance of flavonoids can be found in
many fruits, vegetables, herbs and tea (Hoensch and Oertel 2011). Many anti-cancer
effects of flavonoids have been identified in cellular colorectal cancer model systems
(Kuo 1996). Further investigation in animal models suggest flavonoids may play a role
in the inhibition of abherrant crypt foci (ACF) and colonic polyps, both of which can be
precursors of colorectal cancer (Miyamoto, Yasui et al. 2010). Clinical and
epidemiological evidence has been mixed, with a number of studies suggesting a
decrease in colorectal cancer risk is associated with flavonoid consumption, whereas
some studies find no significant correlation exists (Theodoratou, Kyle et al. 2007; Bobe,
Sansbury et al. 2008; Nimptsch, Zhang et al. 2016). Remarkably, other clinical findings
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have shown flavonoids can decrease the recurrence of colon cancer tumors after surgical
removal (Hoensch, Groh et al. 2008).
More than 4000 flavonoids have been identified and are categorized based on
their structure. The flavonoid basic structure consists of two benzene rings (A and B)
connected with three carbons in an oxygenated heterocycle ring (C) (Liu 2004). It is
variations on this C ring that determines the organization of the flavonoids into six
different subgroups most commonly found in the diet as flavones, flavonols, flavanols,
flavanones, anthocyanidins and isoflavones (Beecher 2003). Notably, of these flavonoid
subgroups the flavones (luteolin, apigenin and nobiletin) have shown significant anticancer effects in animal and cellular models of colorectal cancer (Figure 2.1).

(A)

(B)

(4',5,7.-trihydroxyflavone)
Apigenin

(3',4',5,7-tetrahydroxyflavone)
Luteolin
3

(C)
Hydrolysis

DDMN
(3',4'-didemethylnobiletin)

Figure 2.1. Chemical structures of (A) apigenin, (B) luteolin and (C) DDMN
(3',4'-didemethylnobiletin)
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Luteolin is found in celery, parsley, apple skin, cabbage, carrots, broccoli and
green peppers. In vitro studies suggest luteolin can operate its effects in multiple cell
signaling pathways associated with colorectal cancer. Researchers using a cellular model
of intestinal inflammation found luteolin treatment to exhibit anti-inflammatory effects
through the inhibition of the JAK/STAT pathway (Nunes, Almeida et al. 2017).
Luteolin treatment in HT29 colon cancer cells initiates the induction of apoptosis and cell
cycle arrest accompanied by a decrease in insulin-like growth factor-1 receptor (IGF-1R)
signaling that leads to a reduction in activation of the PI3K/Akt and ERK1/pathways
(Lim, Cho et al. 2012). Chemotherapeutic resistant colon cancer cell lines treated with
luteolin were found to have increased sensitivity to oxaliplatin’s anticancer effects; these
results appear to be correlated with inhibition of the Nrf2 pathway and HO-1 expression
(Chian, Li et al. 2014). Aberrant crypt foci (ACF) are one of the first signs of
carcinogenic change that occurs in the colonic mucosa followed by the formation of
colonic polyps which potentially can lead to the development of colon cancer. Luteolin
appears to operate in both the initiation and promotion stage of the colorectal
carcinogenic process. Treatment with luteolin significantly decreased the occurrence of
aberrant crypt foci (ACF) in azoxymethane (AOM) induced colon carcinogenesis in mice
(Ashokkumar and Sudhandiran 2008). In studies utilizing the dimethylhydrazine
(DMH)-induced animal model of colon carcinogenesis in rats, luteolin treatment
significantly decreased colon cancer incidence, number of colonic polyps and tumors,
both in number and size (Manju and Nalini 2007; Osman, Said et al. 2015).
Apigenin, a flavone found in chamomile, grapefruit, onions, celery and parsley
has been credited for its’ powerful anti-carcinogenic and anti-tumor effects (Shukla and
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Gupta 2010). Moreover, apigenin has been shown to favorably modulate cell cyclerelated signaling proteins such as p53 and p21; both important for the regulation of cell
cycle progression in colorectal carcinogenesis. Apigenin appears to stabilize p53 in
normal cells but also displays anti-cancer effects in p53 mutant cells. A p53 independent
mechanism is responsible for apigenin induced G2/M cell cycle arrest and upregulation
of p21 expression in the p53 mutant colon cancer cell line HT29 (Takagaki, Sowa et al.
2005). Examination of HCT116 p53 wild-type colon cancer cells following apigenin
treatment revealed a dose dependent suppression of cell proliferation with G2/M cell
cycle arrest accompanied by increased expression of p53 and p21 (Lee, Sung et al. 2014).
Additional investigation by Zhong et al in Apcmin+ mice, a colorectal cancer animal
model, discovered apigenin treatment resulted in a decrease in polyp number and a
concurrent increase in p53 activation (Zhong, Krisanapun et al. 2010). Other animal
models of colon carcinogenesis have displayed similar positive effects with an inhibition
of ACF in the distal region of the mouse colon and a decreased number of high
multiplicity ACF observed following apigenin treatment in azoxymethane (AOM)
induced CF-1 mice and AOM treated rats respectively (Au, Li et al. 2006; Leonardi,
Vanamala et al. 2010).
Nobiletin a polymethoxyflavone (PMF), is found primarily in the peel of sweet
(C. sinensis) and bitter (C. aurantium) orange. Accumulating evidence reveals nobiletin
can operate in multiple signaling cascades associated with various disease processes to
bring about positive effects (Luo, Guan et al. 2008; Lee, Cha et al. 2010; Huang, Li et al.
2016). In addition, studies indicate nobiletin is effective in the inhibition of colorectal
cancer cell growth with G1 cell cycle arrest and upregulation of p21 (Morley, Ferguson et
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al. 2007; Wu, Song et al. 2015). Results from preclinical studies using animal models
confirm these cellular findings. In AOM /DSS treated mice expression of p21 and p53
were upregulated in colonic mucosa following nobiletin dietary treatment; these findings
were associated with a significant reduction in incidence and multiplicity of colonic
tumors (Wu, Song et al. 2015). Nobiletin dietary treatment resulted in the inhibition of
ACF, decreased cell proliferation and expression of prostaglandin E2 in the colonic
mucosa of azoxymethane (AOM)-induced rat colon carcinogenesis (Kohno, Yoshitani et
al. 2001; Suzuki, Kohno et al. 2004). Similar findings in F344 rats revealed nobiletin
significantly reduced the number of colonic aberrant crypt foci (Tang, Ogawa et al.
2011).
Flavonoid metabolites are of great interest to researchers as they are present at
higher concentrations than their parent compounds in both blood and colonic tissue;
therefore it is likely the metabolites are responsible for many of the positive effects.
Accumulating evidence appears to suggest flavonoid metabolites have different
biological and antioxidant properties than their associated parent compound, often more
potent in their response (Williamson and Clifford 2010; Lotito, Zhang et al. 2011).
Nobiletin and its major metabolites as a mixture, in the same proportion as that found in
the colon of mice fed nobiletin, upregulated the Nrf-2 pathway in RAW 264.7 cells and
increased expression of p53 in HCT116 colon cancer cells (Wu, Song et al. 2017).
Colonic concentration of nobiletin in the mouse is much lower than its three primary
metabolites of which 3',4'-didemethylnobiletin (DDMN) has been identified as the
metabolite with the strongest anti-proliferative effects in HCT116 colon cancer cells (Wu,
Song et al. 2015). DDMN appears to inhibit multiple signaling pathways associated with
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inflammation and carcinogenesis (Lai, Li et al. 2008; Su, Yen et al. 2012). Recent
findings have shown 3',4'-didemethylnobiletin (DDMN), a primary metabolite of
nobiletin in the mouse to have even stronger anti-inflammatory and anti-cancer effects
than its parent compound nobiletin (Li, Sang et al. 2007; Lo, Pan et al. 2010; Su, Yen et
al. 2012; Wu, Song et al. 2015). Indeed, anti-inflammatory properties of DDMN have
been identified in RAW264.7 cells with DDMN exhibiting potent inhibition in the
induction of iNOS, such that it greatly exceeds nobiletin’s anti-inflammatory response
(Li, Sang et al. 2007). DDMN initiates G2/M cell cycle arrest with an upregulation of
p21 in HCT116 colon cancer cells; demonstrating stronger growth inhibition and
induction of apoptosis than nobiletin in both HCT116 and HT29 cell lines (Wu, Song et
al. 2015).
Combination of dietary components has shown many enhanced effects in various
cancers (DiMarco-Crook and Xiao 2015). Multiple pathways dysregulated in the
carcinogenic process warrants the use of several components with complementary
mechanisms. Although many studies have examined the positive effects of individual
flavonoids, few animal or clinical studies have investigated flavonoid to flavonoid
combinations in colorectal cancer; however some positive findings have been reported
(Tanaka, Makita et al. 1997; Hoensch, Groh et al. 2008). In a small clinical study of 29
patients with resected colon cancer and polyp removal half were given a combination of
20mg apigenin and 20mg epigallocatechin-gallate, (found in green tea) and matched to
untreated controls. Interestingly, the untreated group had a 47% recurrence rate of colon
cancer whereas the flavonoid treatment group had only a 7% recurrence. Synergistic
anti-inflammatory and anti-oxidant effects have also been reported in RAW 264.7 cells
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with a number of flavonoid to flavonoid combinations (Harris, Qian et al. 2006; Funaro,
Wu et al. 2016; Phan 2017). Moreover, multiple colorectal cancer cell lines including
HCT116, HT29, SW480 and Caco-2 cells have been used with flavonoid to flavonoid
combination treatments and have demonstrated significant synergistic inhibition of cell
proliferation (Wang, VanAlstyne et al. 2004; Lambert, Kwon et al. 2008; Gomez-Alonso
2012; Jaramillo-Carmona 2014). Remarkably, no studies have been done thus far to our
knowledge using a combination treatment of a flavonoid to flavonoid metabolite to
examine the inhibition of cell growth in colorectal cancer.
Based on these findings, the aim of this study is to examine the anti-proliferative
effects in HCT116 colon cancer cells of two structurally related flavones, apigenin or
luteolin in combination with 3'4'- didemethylnobiletin (DDMN), a primary metabolite of
nobiletin in the mouse. Although apigenin, luteolin and DDMN are each effective in the
inhibition of HCT116 colon cancer cells individually no information currently exists
examining the potential synergy, additive or antagonistic effects of either flavone in
combination with the metabolite DDMN. Therefore, for the first time this study
distinguishes between the structurally related flavones apigenin or luteolin and their
interaction with the flavone metabolite DDMN to determine their combinatory antiproliferative effects in HCT116 colon cancer cells.

2.5

Materials and Methods

2.5.1

Cell Culture
HCT-116 human colon cancer cells were purchased from American Type Cell

Collection (ATCC, Manassas, VA, USA). RPMI 1640 media (Mediatech, Herndon, VA,
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USA) comprised of 5% fetal bovine serum (FBS), 100U/ml of penicillin and 0.1mg/ml of
streptomycin was used as the growth medium for the cells and changed every several
o

days. The HCT116 colon cancer cells were held in an incubator at 37 C with 5% CO

2

and the cells selected for the experiments were between 3 to 25 passages.

2.5.2

Cell Treatments

Luteolin (>98%) and apigenin ( >98%) were obtained from Quality Phytochemicals Inc.
(Edison, New Jersey). The 3', 4'-didemethylnobiletin (DDMN, 98%) was produced after
a multi-step process with its chemical structure verified using MS and NMR spectra
methods as described (Li, Pan et al. 2007; Li, Sang et al. 2007). DMSO was used for the
delivery of DDMN and curcumin to the cells in each experiment, resulting in a final
concentration of 0.1% DMSO.

2.5.3

Cell Viability Assay
HCT-116 cells were seeded at 2,000 cells per well in 96-well plates and

treatments of DDMN, apigenin, luteolin or their combination were administered in serial
concentrations after 24 hour incubation in 200 µl of serum complete media. Once the
associated treatment times were met, the replacement of media with 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) containing media (SigmaAldrich) was performed to quantify cell viability as outlined in prior experiments (Qiu,
Dong et al. 2010).
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2.5.4

Analyses of Synergy
The analyses of synergy utilized a linear regression model based on the Chou

Talahay method with some alterations as previously described (Chou and Talalay 1984;
Xiao, Zhang et al. 2008; Guo, Qiu et al. 2012). Results were examined using the R
program and synergy was categorized utilizing the interaction index parameters, with the
combination interaction (CI) characterized as exhibiting additivity (=1), synergy (<1), or
antagonism (>1).

2.6

Results and Discussion

2.6.1

Apigenin and DDMN Additively Inhibit Cell Viability in HCT116 Colon

Cancer Cells
HCT116 human colon cancer cells were treated with serial doses of DDMN
(3µM-15µM) and apigenin (3µM-15µM) individually and at half-dose serial
concentrations in combination for 48 hours to determine growth inhibitory effects using
the MTT assay. Cell viability as measured by the MTT assay revealed that combined
treatment with DDMN and apigenin exhibited growth inhibitory effects after 48 hours of
compound exposure (Figure 2.2). Individual treatment with DDMN alone provided only
minimal inhibition of growth (13%-15%) at low concentrations (3µM-6µM) but was
substantially more effective at inhibition of growth (30%) with the highest concentration
(15µM). Apigenin individual treatment exhibited a dose dependent response with a much
stronger inhibition (18%-91%) of growth at all concentrations (3µM-15µM) than
DDMN. Combination of DDMN and apigenin at half-dose serial concentrations
inhibited cell viability in a dose dependent manner with an additive effect that appeared
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to not greatly differ from the individual treatment effects therefore no apparent
interaction occurred as determined by the combination index previously described.
Additive was defined as combination interaction index CI = 1.
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Figure 2.2 Growth inhibitory effects of apigenin and DDMN individually and in
combination following serial concentrations of compound treatments in HCT116 human
colon cancer cells. Cell viability was measured by MTT assay as previously described in
Section 2.2.
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Figure 2.3 Combined treatment with apigenin and DDMN exhibited additive growth
inhibitory effects after 48 hr of compound exposure. (A) Median effect plot of apigenin,
DDMN and their combination on growth inhibition of HCT116 cells. (B) Interaction index
plot for the combination effects of apigenin and DDMN on growth inhibitory effects of
HCT116 colon cancer cells. Additive was defined as CI interaction index = 1. Median
effect plot and interaction index plot constructed as described in Materials and Methods.
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2.6.2

Luteolin and DDMN Demonstrate Antagonism in the Inhibition of Cell

Viability in HCT116 Colon Cancer Cells
HCT116 human colon cancer cells were treated with serial doses of DDMN
(3µM-15µM) and luteolin (3µM-15µM) individually and at half-dose serial
concentrations in combination for 48 hours to determine growth inhibitory effects using
the MTT assay. Cell viability as measured by the MTT assay revealed that combined
treatment with DDMN and luteolin displayed growth inhibitory effects after 48 hours of
compound exposure (Figure 2.3). Individual treatment with DDMN alone provided
inhibition of growth (25%-32%) at low concentrations (3µM-6µM) but was substantially
more effective at inhibition of growth (56%) with the highest concentration (15µM).
Luteolin individual treatment exhibited a dose dependent response with a similar
inhibition (23%-56%) of growth at all concentrations (3µM-15µM) as DDMN. The
combination of DDMN and luteolin at half-dose serial concentrations inhibited cell
viability in a dose dependent manner exhibiting an antagonistic effect of less inhibition
than the individual treatments separately, as determined by the combination index
previously described. Antagonism was defined as combination interaction index CI > 1.
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Figure 2.4 Growth inhibitory effects of luteolin and DDMN individually and in
combination following serial concentrations of compound treatments in HCT116 human
colon cancer cells. Cell viability was measured by MTT assay as previously described in
Section 2.2.
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Figure 2.5 Combined treatment with luteolin and DDMN exhibited antagonistic growth
inhibitory effects after 48 hr of compound exposure. (A) Median effect plot of luteolin,
DDMN and their combination on growth inhibition of HCT116 cells. (B) Interaction index
plot for the combination effects of luteolin and DDMN on growth inhibitory effects of
HCT116 colon cancer cells. Antagonism was defined as CI interaction index > 1. Median
effect plot and interaction index plot constructed as described in Materials and Methods.
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2.6.3

Discussion
Studies identifying specific vegetables and fruits exhibiting anti-proliferative

activity conclude the inhibitory effects on cellular growth are likely due to individual
components or a class of phenolic components present in the vegetable or fruit (Chu, Sun
et al. 2002; Sun, Chu et al. 2002). Flavonoids are one such group of polyphenolic
compounds found abundantly in vegetables and fruits (Liu 2004). A number of flavonoid
interactions have been described as synergistic with enhanced anti-proliferative, antioxidant and anti-inflammatory effects (Freeman, Eggett et al. 2010; Hidalgo 2010;
Gomez-Alonso 2012; Jaramillo-Carmona 2014). Although studies suggest flavonoids in
combination can contribute to greater health promoting effects; other findings are mixed,
pointing to the need to investigate flavonoids in combination to determine if their positive
attributes are unchanged (additive) or negatively impacted resulting in antagonistic
effects and diminished benefit (Freeman, Eggett et al. 2010; Colon and Nerin 2016). In
addition, few studies have examined the combination of a flavonoid with a flavonoid
metabolite offering the potential for greater anti-cancer effects using a colon cancer
cellular model. Therefore, we report for the first time on the anti-proliferative effects of
luteolin or apigenin both flavones, in combination with 3',4'- didemethylnobiletin
(DDMN), a primary metabolite of the flavone nobiletin in the mouse in HCT116 colon
cancer cells; findings indicate no interaction (additive) between apigenin and the
metabolite occurred whereas an antagonistic combination response with luteolin and
DDMN appears to exist. These results suggest the flavones although similar in structure
can display divergently different interactions with the metabolite of a
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polymethoxyflavone, exhibiting a range of response from no additional benefit to a
reduction in anti-proliferative effectiveness.
Multiple studies have explored the relationship between the flavonoid structure
and its anti-proliferative, anti-oxidant and/or anti-inflammatory effects (Kuo 1996;
Chidambara Murthy, Kim et al. 2012). Results indicate flavonoid inhibition of cell
growth is associated with the presence of a double bond at C2-C3 of which luteolin,
apigenin and DDMN all possess; additional variations of the C ring appear to be
accompanied by a reduction or loss of inhibitory activity (Agullo, Gamet-Payrastre et al.
1996; Depeint, Gee et al. 2002; Chang, Mi et al. 2008). Some researchers report
heightened or diminished inhibition of cell growth can occur by flavonoids due to the
location and/or number of hydroxyl groups on the flavonoid structure; whereas others
find anti-proliferative effects do not appear to be impacted by hydroxyl group variations
(Agullo, Gamet-Payrastre et al. 1996; Kuntz, Wenzel et al. 1999; Chang, Mi et al. 2008;
Chidambara Murthy, Kim et al. 2012). The structure of apigenin (4',5,7trihydroxyflavone) and luteolin (3',4',5,7-tetrahydroxyflavone) differ only in one
hydroxyl group located on the B ring at the 3' position that luteolin contains but apigenin
does not (Figure 2.1). Free radical scavenging activity has been associated with a greater
number of hydroxyl groups on the B ring particularly the di-hydroxy at 3' and 4' is very
important for strong radical absorbing activity; therefore luteolin exhibits a higher
antioxidant activity with its di-hydroxy groups at 3' and 4' position as compared to
apigenin that lacks a hydroxyl group at the 3' position (Rice-Evans, Miller et al. 1996;
Kumar and Pandey 2013). Additional anti-oxidant and anti-inflammatory effects appear
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to be correlated with the presence of the di-hydroxy groups at 3' and 4' (Cao, Sofic et al.
1997; Ueda 2002).
Polymethoxylated flavonoids (PMFs) such as nobiletin, have a benzo-γ-pyrone
structure with a minimum of four methoxyl groups on the A, B and/or C ring (Li 2008;
Ho 2012). High anti-proliferative activity has been associated with a C-8 methoxyl group
as part of the polymethoxyflavone structure in a number of cancer cell lines (Kawaii,
Tomono et al. 1999). Biotransformation of nobiletin (5,6,7,8,3',4'-hexamethoxyflavone)
occurs on the B ring at the 3' and 4' positions; such that 3',4'-didemethylnobiletin (Figure
1), a primary metabolite of nobiletin in CD-1 mice has recently been identified and found
to have greater anti-proliferative, anti-oxidant and anti-cancer effects than the parent
compound nobiletin (Li 2009). In contrast, other flavonoid metabolites are reported to
have diminished anti-proliferative effects as compared to their parent compound
(Delgado, Fernandes et al. 2014). Indeed, accumulating research of flavonoids and their
metabolites suggests the number of methoxyl and hydroxyl groups and their position on
the flavonoid structure can greatly influence their biological effects and antioxidant
capacity (Rice-Evans, Miller et al. 1996; Tripoli 2007; Li 2008; Hidalgo 2010; Lotito,
Zhang et al. 2011; Delgado, Fernandes et al. 2014; Kongpichitchoke, Hsu et al. 2015;
Chen, Teng et al. 2016).
The concentrations used in this study for apigenin, luteolin and DDMN
suppressed cell growth at all concentrations in a dose dependent manner (Figures 2.2 &
2.3). Individual treatment with apigenin was substantially more potent in its inhibitory
effects than individual treatment with luteolin or DDMN. The absence of a hydroxyl
group at the 3' position of apigenin does not have a diminished effect on apigenin’s
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individual anti-proliferative inhibition in this study using HCT116 colon cancer cells;
rather apigenin exceeds luteolin in its inhibition of cell growth demonstrating the lack of
a 3' hydroxyl group is associated with a greater reduction of cell proliferation in this cell
line. The anti-proliferative effects of the individual compounds on HCT116 colon cancer
cells were greatest in apiginen > luteolin > DDMN based on their inhibitory potency in
this study. These findings are in agreement with the results of a comparison study of
different flavones to determine their inhibition of HCT116 colon cancer cells;
researchers found apigenin to exhibit the strongest anti-cancer inhibitory effects of
decreased cell proliferation of all the flavones tested, including luteolin (Zhong,
Krisanapun et al. 2010). In contrast, Manthey et al conducted a comparison of the antiproliferative actions of flavones in HT29 colon cancer cells and found luteolin to have
greater inhibitory effects than apigenin (Manthey and Guthrie 2002). Similarly, using the
same HT29 cell line other researchers find flavonoids that lack the 3' hydroxyl (such as
apigenin) are not as effective in the inhibition of cell growth as those with the 3' hydroxyl
as a part of their flavonoid structure (Agullo, Gamet-Payrastre et al. 1996). Based on
these findings and the results of this study, cell specificity appears to be involved in the
measured anti-proliferative response of apigenin or luteolin in different colon cancer cell
lines.
DDMN, a metabolite of nobiletin in the mouse was not examined in either of the
aforementioned comparison studies however DDMN’s dose dependent suppression of
cell growth in this study is consistent with the anti-proliferative effects of DDMN
previously described by Wu et al in HCT116 colon cancer cells (Wu, Song et al. 2015).
Both luteolin and DDMN contain a di-hydroxy at the 3'- and 4'-position of the B-ring and
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differ structurally only in the A-ring of which luteolin has hydroxyl groups at the 5- and
7-position whereas DDMN contains methoxyl groups at the 5-, 6-, 7- and 8-position. As
such, DDMN structurally distinct from luteolin, with methoxyl groups on the A-ring is
found in this study to be associated with a smaller anti-proliferative effect than that
observed in luteolin in HCT116 colon cancer cells.
Luteolin and apigenin both flavones, have displayed synergism in the
enhancement of anti-proliferative and anti-carcinogenic properties when combined with
flavonoids in several cellular models of cancer (Amin, Wang et al. 2010; Shih, Liu et al.
2010; Huang, Wei et al. 2016). A synergistic combinatorial effect is likely due to
complimentary mechanisms of food components used in combination; as such an
antagonistic interaction could occur in a combination of food components with opposing
mechanisms, however more research is needed as much remains to be determined (Pappa,
Strathmann et al. 2007; Funaro, Wu et al. 2016). Our findings suggest the combinations
of DDMN with apigenin or luteolin are not synergistic in the inhibition of cell
proliferation; such that no interaction is apparent between DDMN and apigenin whereas
an antagonistic interaction appears to occur in the combination of DDMN with luteolin
(Figures 2.4 & 2.5).
Although the results of this study can indicate the nature of the interaction and its
effects on anti-proliferation in combination these findings cannot determine causative
mechanisms; they do however warrant further investigation through examination of the
literature regarding luteolin’s antagonistic interactions with other food components to
offer insight into our finding of an antagonistic combination of luteolin and DDMN.
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Luteolin has been reported to exhibit an antagonistic interaction with another
flavone in several research studies. Notably, luteolin appears to have an antagonistic
effect on the polymethoxyflavone nobiletin, the parent compound of DDMN in Caco-2
colon cancer cells, an intestinal absorption model; luteolin inhibited nobiletin uptake by
26%, researchers speculate this finding suggests the two flavones share the same
transporter perhaps due to the similarity of their structures (Kimura, Ohta et al. 2014). In
this study, the metabolite DDMN structurally distinct from its parent compound nobiletin
containing a di-hydroxy at 3' and 4'of the B ring exhibits an antagonistic interaction with
luteolin upon examination of anti-proliferative effects in HCT116 colon cancer cells.
Indeed, the difference in structure of apigenin and luteolin suggests the absence of the 3'
hydroxyl is associated with no interaction or an additive response when apigenin is
combined with DDMN whereas the presence of the 3' hydroxyl on the luteolin structure
is associated with an antagonistic response with diminished anti-proliferative effects in
combination with DDMN. The ratio or proportion of luteolin that is used in combination
has also been shown to be influential in determining an antagonistic or synergistic
interaction with apigenin in the examination of cell cycle arrest. In SW480 p53 mutant
colon cancer cells, the combination of luteolin at low concentrations (5µM-30µM) with
apigenin at 20µM, significantly increased G2/M cell cycle arrest whereas luteolin at high
concentrations (>30µM) combined with apigenin at 20µM resulted in antagonism with a
significant decrease in the level of G2/M cell cycle arrest (Wang, VanAlstyne et al.
2004). The low concentrations of luteolin (3µM-15µM) used in this study in
combination with the low concentrations of DDMN (3µM-15µM) were not synergistic in
the suppression of cell growth rather luteolin in low concentrations exhibited antagonism
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in a dose dependent manner when combined with DDMN resulting in a decreased antiproliferative effect in HCT116 p53 wild-type colon cancer cells.
Interestingly, luteolin has recently been identified as a negative regulator of p53
with the significant down-regulation of p21, a downstream target of p53 that is involved
in mediating G2 cell cycle arrest in HCT116 p53 wild type colon cancer cells (Sakai
2012). In contrast, both DDMN and apigenin individually have been found to
significantly increase the induction of p21 in HCT116 p53 wild type cells (Zhong,
Krisanapun et al. 2010; Wu, Song et al. 2015). As such, further research is warranted to
explore whether an antagonistic interaction between luteolin and DDMN in HCT116 p53
wild type colon cancer cells could potentially occur in part due to luteolin possessing an
opposing mechanism to DDMN in the regulation of p53 and subsequent downregulation
of p21.

2.7 Conclusion
In summary, we report for the first time to our knowledge luteolin in combination
with 3',4'-didemethylnobiletin (DDMN), the primary metabolite of nobiletin in the
mouse, to exhibit antagonism in the inhibition of anti-proliferative effects in HCT116
colon cancer cells. Furthermore, these antagonistic effects appear to be associated with
the presence of the 3' hydroxyl group on the B-ring of luteolin. Taken together, more
research is needed to fully characterize the mechanism responsible for this antagonistic
combinatory interaction of luteolin with DDMN and to determine if diminished antiproliferative effects occur in other flavonoid metabolite combinations.
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CHAPTER 3
SYNERGISTIC ANTI-CANCER EFFECTS OF CURCUMIN AND FLAVONOID
METABOLITE IN COMBINATION FOR CHEMOPREVENTION OF
COLORECTAL CANCER

3.1

Abstract

Chemoprevention strategies employing the use of multiple dietary bioactive components
in combination offer advantages due to their relative low toxicity and potential
synergistic interactions, however research is needed to determine their overall
combination effects. Herein, we evaluate the combination of curcumin and 3', 4'
didemethylnobiletin (DDMN) a primary metabolite of nobiletin in the mouse, to
determine their anti-carcinogenic combinatory effects in HCT116 colon cancer cells.
Isobologram analysis reveals a synergistic interaction exists between curcumin and
DDMN in the inhibition of colon cancer cell growth in HCT116 colon cancer cells.
Additionally, combination treatment induced significant G2/M cell-cycle arrest and
extensive apoptosis, which greatly exceeded the effects of individual treatments with
curcumin or DDMN. Proteins associated with these heightened anti-carcinogenic effects
were p53, p21, HO-1, c-PARP, cdc2 and cdc25c; each of the proteins was confirmed to
be substantially impacted by the combination treatment, more than by individual
treatments alone. This newly identified synergy between curcumin and DDMN should
be explored further to determine its chemopreventive value and potential contribution to
colorectal cancer in vivo.
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3.2

Keywords:

Dietary bioactive components, combination, cancer chemoprevention, colorectal cancer,
flavonoid metabolite, curcumin, turmeric, nobiletin, polymethoxyflavone, synergistic
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Abbreviations

DDMN: 3',4'-didemethylnobiletin; ACF: aberrant crypt foci; PMF: polymethoxyflavone;
AOM: azoxymethane; DMH: dimethylhydrazine

3.4

Introduction
Dietary bioactive components offer a viable option to current therapies for many

diseases as they appear to be beneficial for their prevention and early treatment through
the modulation of deregulated signaling pathways (Garcia-Lafuente, Guillamon et al.
2009; Pan, Lai et al. 2009; Tunon, Garcia-Mediavilla et al. 2009). Colorectal cancer is a
complex disease characterized by multiple deregulated signaling pathways that are
responsible for the promotion and progression of the carcinogenic process (Bird 1995).
Multi-drug therapy is often used in the treatment of cancer as an alternative to targeting
one gene or one signaling cascade; however toxicity and dosage tolerance remains a
concern (Goldin and Mantel 1957; Humphrey, Brockway-Lunardi et al. 2011). Similarly,
the use of drugs for the chemoprevention of colorectal cancer are limited due to
undesirable side effects associated with their long-term use (Psaty and Potter 2006; Das,
Arber et al. 2007; DuPont, Arguedas et al. 2007). Numerous in vitro and in vivo studies
have highlighted the anti-carcinogenic effects of natural compounds found in food
(Tsuda, Ohshima et al. 2004; Chen and Kong 2005; Fresco, Borges et al. 2006).
Accumulating evidence suggests dietary bioactive components in combination may play
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an important role in the chemoprevention of many cancers (DiMarco-Crook and Xiao
2015). Indeed, a multi-agent strategy of combination treatment utilizing several bioactive
components is desirable as the dietary components are likely to have complementary
effects thereby eliciting a more powerful anti-inflammatory and anti-cancer response with
low toxicity (Liu 2003; Murakami, Takahashi et al. 2003; Rather, Bhat et al. 2013;
DiMarco-Crook and Xiao 2015). .
Polymethoxyflavones (PMFs) are a group of dietary bioactive components being
investigated for their beneficial effects; a class of citrus flavonoids found primarily in
citrus peel that have demonstrated anti-carcinogenic properties in a variety of cancer
model systems (Sergeev, Ho et al. 2007; Xiao, Yang et al. 2009; Qiu, Dong et al. 2010;
Lai, Tsai et al. 2011). PMFs also appear to offer an increased potential for absorption
and bioavailability as compared to their polyhydroxylated flavonoid counterparts; due to
the methoxyl groups on the PMF structure PMFs are more lipophilic and thus may result
in higher permeability of the small intestine and subsequent higher absorption into the
bloodstream (Li, Lo et al. 2006). Nobiletin, a polymethoxyflavone of particular interest
has been reported to inhibit carcinogenesis in colon, prostate and breast cancer models
(Tang, Ogawa et al. 2011; Chen, Ono et al. 2014). Notably, 3',4'-didemethylnobiletin
(DDMN), the second most abundant metabolite of nobiletin in the mouse and the most
potent of the metabolites, is reported to be present at a much higher concentration in
mouse colonic mucosa than nobiletin; therefore, these findings suggest many of the
observed positive effects of nobiletin could be attributed to its’ metabolite DDMN
(Zheng, Bi et al. 2015). Indeed, numerous research studies demonstrate
3',4'didemethylnobiletin (DDMN) a primary metabolite of nobiletin in the mouse (Figure
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1), exhibits a much stronger anti-oxidant, anti-inflammatory and anti-carcinogenic
response than the parent compound nobiletin (Li, Sang et al. 2007; Lai, Li et al. 2008; Lo,
Pan et al. 2010; Su, Yen et al. 2012).

Hydrolysis

DDMN
(3’,4’-didemethylnobiletin)

Curcumin

Figure 3.1 Chemical Structures of DDMN (3',4'-didemethylnobiletin) and curcumin
Curcumin, a bioactive component found in turmeric, (Figure 3.1) has been
investigated as an alternative strategy for the chemoprevention of colorectal cancer and is
widely credited for its anti-carcinogenic effects that include the downregulation of proinflammatory signaling cascades, initiation of cell cycle arrest and induction of proapoptotic pathways (Teiten, Eifes et al. 2010; Chen, Wang et al. 2014). The frequent use
of turmeric in the diet among residents of India and the low occurrence of colorectal
cancer reported within this population has led researchers to explore the role of curcumin
in the chemoprevention of colorectal cancer (Ferrucci, Daniel et al. 2010; Park and
Conteas 2010). Indeed, an accumulating body of research demonstrates curcumin
operates within the same deregulated signaling pathways associated with the
development of colorectal cancer, yet without the reported negative side effects of
chemopreventive drugs. Although curcumin has displayed limited bioavailability in
vivo, clinical studies examining curcumin intervention in patients for the prevention and
treatment of colorectal cancer have generated positive preliminary findings of anti-cancer
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effects (Carroll, Benya et al. 2011; Gupta, Patchva et al. 2013). Direct contact of
curcumin with the colon overcomes some of the bioavailability challenge; however an
effective combination treatment utilizing curcumin can also be beneficial in lowering the
dosage required to obtain the maximum treatment effect of curcumin in vivo.
Curcumin and polymethoxyflavones (PMFs) have interacted synergistically with
a number of other dietary bioactive components in combination, however no information
currently exists that examines the anti-cancer effects of the combination of curcumin with
a polymethoxyflavone metabolite in colon cancer. (Majumdar, Banerjee et al. 2009;
Pesakhov, Khanin et al. 2010; Guo, Qiu et al. 2012; Funaro, Wu et al. 2016). Based on
this information we will evaluate for the first time the anti-cancer inhibitory effects of the
combination of curcumin and 3',4'-didemethylnobiletin (DDMN), a primary metabolite of
nobiletin in the mouse, in the HCT116 human colon cancer cell line.

3.5

Materials and Methods

3.5.1

Cell Culture

HCT-116 human colon cancer cells were purchased from American Type Cell Collection
(ATCC, Manassas, VA, USA). RPMI 1640 media (Mediatech, Herndon, VA, USA)
comprised of 5% fetal bovine serum (FBS), 100U/ml of penicillin and 0.1mg/ml of
streptomycin was used as the growth medium for the cells and changed every several
o

days. The HCT116 colon cancer cells were held in an incubator at 37 C with 5% CO
and the cells selected for the experiments were between 3 to 25 passages.
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3.5.2

Cell Treatments

Curcumin (96%) was obtained from Quality Phytochemicals, LLC (New Jersey, USA).
The 3', 4'-didemethylnobiletin (DDMN, 98%) was produced after a multi-step process
with its chemical structure verified using MS and NMR spectra methods as described (Li,
Pan et al. 2007; Li, Sang et al. 2007). DMSO was used for the delivery of DDMN and
curcumin to the cells in each experiment, resulting in a final concentration of 0.1%
DMSO.

3.5.3

Cell Viability Assay

HCT-116 human colon cancer cells were seeded in 96-well plates and treatments of
DDMN, curcumin or their combination were administered in serial concentrations after
24 hour incubation. Once the associated treatment times were met, the replacement of
media with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
containing media (Sigma-Aldrich) was performed to quantify cell viability. Further detail
as outlined above and in prior experiments (Qiu, Dong et al. 2010).

3.5.4

Analyses of Synergy

The analyses of synergy utilized a linear regression model based on the Chou Talahay
method with some alterations as previously described (Chou and Talalay 1984; Xiao,
Zhang et al. 2008; Guo, Qiu et al. 2012). Results were examined using the R program
and synergy was categorized utilizing the interaction index parameters, with the
combination interaction (CI) characterized as exhibiting additivity (=1), synergy (<1), or
antagonism (>1).
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3.5.5

Cell Cycle Analyses

HCT-116 cells were seeded in 6-well plates at a rate of 8 x 104 cells per well. Once cells
were attached following 24h incubation, treatments of DDMN, curcumin or their
combination were added to cells for another 24h incubation period. In preparation for
analysis following incubation, previously adhered cells were removed using trypsin
((0.25% trypsin-EDTA; Mediatech) and were combined with the floating cells. Further
steps necessary for analysis were undertaken as previously described (Qiu, Dong et al.
2010). BD LSRII flow cytometry was used to examine cell cycle distribution and the
subsequent data produced was analyzed with Modifit LT software.

3.5.6

Apoptosis Detection

HCT-116 cells were seeded in 6-well plates (8 x 104 cells per well), incubated for 24
hours and prepared for analysis as outlined above. Apoptotic cells were calculated
following 48h treatments using BD LSRII flow cytometry and the Annexin V/PI double
staining assay to distinguish between early apoptotic cells as Annexin V-positive/PInegative cells and late apoptotic cells as Annexin V-positive/PI-positive cells.

3.5.7

Immunoblotting

HCT-116 cells were seeded in 15cm petri dishes, incubated for 24h and then treated with
DDMN, curcumin or their combination for another 24h or 48h incubation. Whole cell
lysate was isolated and retrieved for each treatment after cells were washed with iced
PBS. Preparation for Western Blot and the subsequent analysis was performed as
previously described (Xiao, Zhang et al. 2008; Qiu, Dong et al. 2010; Guo, Qiu et al.
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2012). Antibodies for p53, p21Cip1/Waf1, poly ADP ribose polymerase (PARP), cdc-2 (cdk1), and cdc25c were each acquired from Cell Signaling Technology (Beverly, MA, USA);
antibody for β-actin was obtained from Sigma Aldrich.

3.5.8

Statistical Analysis

Results are conveyed as the mean ± standard deviation (SD). To compare the differences
between more than 2 groups the analysis of variance model (ANOVA) was used. In
addition, for multiple comparisons the Post-hoc test Tukey Range Honesty Significant
Difference was employed. A 1% level of significance was established for all tests.

3.6 Results and Discussion
3.6.1

Curcumin and DDMN Synergistically Inhibit Cell Viability in HCT116

Colon Cancer Cells
HCT116 human colon cancer cells were treated with serial dosages of DDMN (3µM15µM) and curcumin (2µM-10µM) individually and at half-dose serial concentrations in
combination for 48 hours to determine growth inhibitory effects using the MTT assay
(Figure 3.2). Cell viability as measured by the MTT assay revealed that combined
treatment with DDMN and curcumin potentiated the growth inhibitory effects after 48
hours of compound exposure. Individual treatment with DDMN alone provided only
minimal inhibition of growth (10%-12%) at low concentrations (3µM-9µM) but was
substantially more effective at inhibition of growth (27%) with the highest concentration
(15µM). Curcumin individual treatment exhibited a dose dependent response with a
much stronger inhibition (20%-79%) of growth at all concentrations (2µM-10µM) than
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DDMN. Remarkably, the combination of DDMN and curcumin at half-dose serial
concentrations synergistically inhibited cell viability in a dose dependent manner with a
more pronounced effect than individual treatments as determined by the combination
index previously described in Section 2.3. Synergy was defined as combination
interaction index CI < 1 (Figure 3.3).

Figure 3.2 Growth inhibitory effects of curcumin and DDMN individually and in
combination following serial concentrations of compound treatments for 72 hours in
HCT116 human colon cancer cells. Cell viability was measured by MTT assay as
previously described in Section 2.2.
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Figure 3.3 (A) Median effect plot of DDMN, curcumin and their combination on growth
inhibition of HCT116 cells. (B) Interaction index plot for the combination effects of
DDMN and curcumin on growth inhibitory effects of HCT116 colon cancer cells. Synergy
was defined as CI interaction index < 1. Median effect plot and interaction index plot
constructed as described in Materials and Methods.
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3.6.2

Combination of Curcumin and DDMN induce extensive apoptosis as
compared to individual compounds in HCT116 Colon Cancer Cells

To investigate the role of apoptosis on the observed inhibition of cell growth, HCT116
colon cancer cells were subjected to 48 hour treatment of 5µM curcumin and 7.5 µM
DDMN alone and in combination then analyzed to determine the level of early and late
apoptotic cells attributed to each treatment (Figure 3.4). Individual treatment
concentrations of 5µM curcumin, 7.5µM DDMN, half dose combination treatment with
2.5µM curcumin+3.75µM DDMN and full dose combination treatment with 5µM
curcumin +7.5µM DDMN were found to increase early apoptotic cells by 5.3-fold, 1.7fold, 5.4-fold and 28.2-fold respectively whereas, the late apoptotic cells increased 3.3fold, 1.7-fold, 3-fold and 7.9-fold respectively. Surprisingly, the full dose combination
treatment resulted in a 28-fold increase in early apoptotic cells, a finding that greatly
exceeded the 5.4-fold increase observed following half dose combination treatment,
similar to the 5.3-fold increase exhibited by curcumin alone. The full dose combination
treatment also exhibited a greater increase in late apoptotic cells of 7.9-fold, more than
double the 3-fold increase produced in response to the half dose combination treatment,
once again similar to the 3.3-fold increase of curcumin alone. These results demonstrated
significant induction of apoptosis by the full dose combination as compared to control
(Figure 3.3), with a substantial increase in early and late apoptotic cells, based on
ANOVA followed by Tukey’s HSD post-hoc test (p< 0.01, n=3).
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Control

DDMN 7.5 µM

Curcumin 5 µM
Live
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Late Apoptosis
Cells
Early Apoptosis
Cells

DDMN 3.75 µM +
Curcumin 2.5 µM

DDMN 7.5 µM +
Curcumin 5 µM

Figure 3.4 Effects of DDMN, curcumin, and DDMN/curcumin full dose combination on
apoptosis in HCT116 colon cancer cells. HCT116 cells were seeded in 6-well plates then
treated with concentrations as noted above at 24 hours. After another 48 hours cells were
collected and apoptosis analyses were performed as previously described. Annexin V/PI
dot plots indicate a much greater intensity in early apoptosis induction by the full-dose
combination treatment as compared to the control or individual treatments.
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Figure 3.5 Quantification of effects by curcumin, DDMN and full-dose combination on
apoptosis in HCT116 colon cancer cells. All data represents the mean ± SD. The
asterisk in the bar charts represents statistical significance of DDMN/curcumin full-dose
combination treatment group as compared to the control, DDMN or curcumin treatment
groups at full concentrations based on ANOVA followed by Tukey’s HSD post-hoc test
(p ˂ 0.01, n=3).
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3.6.3

Combination of Curcumin and DDMN exhibits greater G2/M cell-cycle
arrest than individual compounds in HCT116 Colon Cancer Cells

To further investigate the mechanism responsible for the anti-proliferative effects of the
combination treatment, cell-cycle analysis was conducted. Figure 3.4 shows the results
of curcumin, DDMN and the combination of curcumin + DDMN on cell-cycle arrest in
HCT116 colon cancer cells. Treatment concentrations of 7.5 µM DDMN and 5 µM
curcumin were evaluated individually, in half dose combination treatment and in full
dose combination treatment in HCT116 cells after 24 hour incubation. Increased G2/M
phase cell-cycle arrest was observed for the individual curcumin treatment (5µM)
although not significant and was much stronger than DDMN individual treatment
(7.5µM) which increased G2/M arrest only nominally. Interestingly, when combined at
half-dose the effect was similar to curcumin alone but a significant accumulation of cells
in the G2/M phase occurred when the full dose combination treatment was examined as
compared to control, based on ANOVA followed by Tukey’s HSD post-hoc test (p <
0.01, n=3).
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Figure 3.6 Effects of DDMN, curcumin, and DDMN/curcumin combination on cell
cycle arrest in HCT116 colon cancer cells. HCT116 cells were seeded in 6-well plates
then treated with concentrations as noted above at 24 hours. After another 24 hours cells
were collected and cell cycle analyses were performed as previously described. Flow
cytometer analyses revealed full-dose combination treatment significantly increased cell
cycle arrest in G2M phase as compared to control or individual treatments.
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Figure 3.7 Quantification of effect by curcumin, DDMN and full-dose combination
treatment on cell cycle in HCT116 colon cancer cells. All data represents the mean ± SD.
The asterisk in the bar chart represents the statistical significance of DDMN/curcumin
full-dose combination treatment to increase G2/M phase cell cycle arrest as compared to
the control, DDMN and curcumin treatment groups at full concentrations based on
ANOVA followed by Tukey’s HSD post-hoc test (p ˂ 0.01, n=3).
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3.6.4

Combination treatment exhibited a pronounced effect on the modulation of
proteins involved in cell-cycle and apoptosis signaling

Additional analysis was conducted to explore the mechanisms responsible for the
heightened cell-cycle G2/M arrest and induction of apoptosis observed following the
combined full dose treatment of curcumin 5µM and DDMN 7.5µM in HCT116 colon
cancer cells. Immunoblot examination of proteins that have been identified to be
involved in these processes revealed the proteins of interest were greatly impacted by the
combination treatment. Indeed, full dose concentrations of curcumin 5µM combined
with DDMN 7.5µM in HCT116 colon cancer cells significantly increased expression of
p21, p53, HO-1 and cleaved PARP whereas the combination significantly decreased
expression of cdc2 and cdc25c (Figure 3.5).
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Control
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Figure 3.8 Effects of curcumin, DDMN and their combination on proteins associated with
cell cycle and apoptosis. Full-dose combination treatment was found to potently alter key
oncogenic markers in HCT 116 colon cancer cells. The number below each protein band
represents the relative intensity of each band as measured by Image J software.

91

3.6.5

Discussion
Combination regimens are increasingly being explored for the chemoprevention

of colorectal cancer (Zhou, Cheng et al. 2012; Mohammed, Janakiram et al. 2013).
Multiple in vitro studies reveal pharmacological agents in combination with natural
dietary bioactive components or their metabolites can result in heightened
chemopreventive effects (Lev-Ari, Strier et al. 2005; Meyskens, McLaren et al. 2008;
Kanthamneni, Chaudhary et al. 2010; Chaudhary, Sutaria et al. 2011; Wu, Song et al.
2017). Interestingly, a growing number of studies suggest several dietary bioactive
components in combination can have similar anti-inflammatory and anti-cancer
properties as observed in pharmacological agent combinations but without the side
effects often associated with their use (Liu 2003; Murakami, Takahashi et al. 2003;
Rather, Bhat et al. 2013; DiMarco-Crook and Xiao 2015). Moreover, the use of two or
more dietary components in combination has been found to exhibit enhanced anticarcinogenic effects in colorectal cancer both in vitro and in vivo (Bose, Hao et al. 2007;
Nakamura, Yogosawa et al. 2009).
The combination of curcumin with pharmacological agents or other dietary
components has been examined for anti-cancer effects in a number of colon cancer model
systems (Lev-Ari, Strier et al. 2005; Cruz-Correa, Shoskes et al. 2006; Howells, Mitra et
al. 2007; Majumdar, Banerjee et al. 2009). This study is the first to examine the
combination of curcumin with 3',4'-didemethylnobiletin, a primary metabolite of
nobiletin in the mouse. Our findings of decreased cellular growth, increased apoptosis
and G2/M cell-cycle arrest in response to individual DDMN or curcumin treatment are
consistent with other researcher’s findings however combination effects have not yet
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been explored (Moragoda, Jaszewski et al. 2001; Wu, Song et al. 2015). This study for
the first time has shown the combination of DDMN (7.5µM) + curcumin (5µM) results in
synergistic inhibition of cell growth, extensive induction of apoptosis and G2/M cellcycle arrest in HCT116 colon cancer cells that is greater than individual treatment effects.
Surprisingly, a significant increase in apoptosis or cell cycle arrest was not observed in
the half dose combination of curcumin (2.5µM) + DDMN (3.75µM) although decreased
cell viability was found to be synergistic at these combination levels. Others have
reported differing mechanisms involved in curcumin’s anti-cancer effects that are
concentration based, with low concentrations of curcumin exhibiting an antioxidant effect
and higher concentrations of curcumin demonstrating a pro-apoptotic effect (Park and
Conteas 2010). A key step that indicates apoptosis has occurred is the cleavage of PARP;
as Figure 3.5 demonstrates after 48 hour treatment the cleavage of PARP was
substantially increased with curcumin (5µM) individual treatment (620%) and DDMN
(7.5µM) individual treatment (70%), however a combined full dose treatment resulted in
a much higher increase (780%) of cleaved PARP. Our findings of increased levels of
cleaved PARP following individual treatment of HCT116 colon cancer cells with DDMN
or curcumin are in agreement with other researcher’s findings (Moragoda, Jaszewski et
al. 2001; Wu, Song et al. 2015). Remarkably, we now find in this study that the
combination of these two compounds results in a more pronounced cleavage of PARP
than by DDMN or curcumin alone.
Proteins p21 and p53, reported to be important for the apoptotic process of many
cancers, were shown to have a heightened increase in expression following DDMN
(7.5µM) + curcumin (5µM) combination treatment as compared to control. After 24 hour
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treatments with DDMN (7.5µM), curcumin (5µM), or full dose (5µM+7.5µM)
combination, expression of p21was elevated by 280%, 300% and 650% respectively,
with the greatest effect observed as a result of the combination treatment. Similarly,
following 24 hour exposure the full dose combination treatment exhibited a substantial
110% increase in p53 expression as compared to control, resulting in a much stronger
response than individual curcumin (70%) or DDMN (10%) treatments. Research
examining the role of p53 and p21 in apoptosis following curcumin treatment has had
mixed findings (Jee, Shen et al. 1998; Choudhuri, Pal et al. 2002; Radhakrishna Pillai,
Srivastava et al. 2004; Watson, Hill et al. 2008; Watson, Hill et al. 2010). Watson et al
suggests curcumin utilizes a p-53 and p-21 independent mechanism to promote apoptosis
in HCT116 colon cancer cells although evidence does exist to suggest that p21 may play
a role in decreasing cell proliferation via cell-cycle arrest. Other researchers compared
curcumin sensitivity in p53 wild type HCT116 colon cancer cells with a p53 knockout
HCT116 cell line to conclude that both wild type p53 and p21 are required for curcumin
sensitivity (Howells, Mitra et al. 2007). Interestingly, clinical findings following
curcumin treatment in colorectal cancer patients suggest a correlation exists between an
increased expression of p53 in tumor tissue with an increase in apoptotic tumor cells and
increased body weight (He, Shi et al. 2011). To our knowledge this is the first time
DDMN has been investigated individually to determine its effect on the expression of
p53 and in our study individual treatment of DDMN at a concentration of 7.5 µM
increased p53 only nominally by 10% as compared to control. Again, we find for the
first time the combination of DDMN and curcumin is more effective in the induction of
p21 and p53 than by individual treatments in HCT116 colon cancer cells.
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Two of the key proteins involved in cell cycle control, cdc2 and cdc25c were
markedly reduced in response to DDMN (7.5µM) + curcumin (5µM) combination
treatment whereas levels of cdc2 and cdc25c showed only a small reduction in expression
following 24 hour exposure to individual compounds of DDMN or curcumin. Cdc2, a
part of the cdc2/cyclinB1 complex that is required to enter mitosis from the G2 phase,
was decreased only nominally by individual treatments of curcumin (5uM) 10% and
DDMN (7.5uM) 20% as compared to control however full dose combination treatment
exhibited a pronounced 50% decrease in expression. Likewise cdc25c, a protein
necessary for the activation of cdc2 was also less impacted by individual treatments with
curcumin or DDMN resulting in a decrease in expression of only 10% and 30%
respectively. In contrast, the combined full dose treatment of curcumin + DDMN
resulted in a dramatic 60% reduction in cdc25c expression. Some research has suggested
the binding of p21 to the cdc2/cyclin B complex can keep cdc2 inactive in the nucleus
preventing cdc25c activation (Collett and Campbell 2004). Interestingly, other
researchers have demonstrated that the addition of p53 to p53-null HCT116 cells down
regulated both cdc2 and cdc25c promoters thereby implicating the involvement of p53 in
the decreased expression of cdc2 and cdc25c (Le Gac, Esteve et al. 2006). Our research
reveals for the first time the decreased expression of cdc2 and cdc25c by DDMN both
alone and in combination with curcumin in HCT116 colon cancer cells. Moreover, we
discovered the combination treatment of DDMN (7.5uM) + curcumin (5uM) markedly
downregulated cdc2 and cdc25c as compared to control and individual treatments.
Heme oxygenase-1 (HO-1), a phase 2 enzyme induced in response to oxidative
stress was found to dramatically increase following our treatment of HCT116 colon
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cancer cells with DDMN (7.5µM), curcumin (5µM) or full dose combination treatment
by 490%, 10% and 770% respectively. Murphy et al reports curcumin treatment of
HCT116 cells resulted in expression of HO-1 accompanied by cell shrinkage, membrane
blebbing, apoptotic bodies and chromatin condensation (Murphy, Testa et al. 2014). To
our knowledge, DDMN’s effect on HO-1 has not yet been explored in a colon cancer
model but DDMN has been found to increase induction of HO-1 in PC12 cells, a cell line
used to study neuronal differentiation and cell death (Su, Yen et al. 2012). Controversy
currently exists regarding the role of HO-1 in carcinogenesis as many reports of HO-1
expression have been associated with a pro-tumor effect that has been implicated in a
variety of different cancers (Jozkowicz, Was et al. 2007). Other pre-clinical findings
suggest an anti-carcinogenic role for HO-1 in prostate and colon cancer (Gueron, De
Siervi et al. 2009; Andres, Fermento et al. 2014). Investigation using a chemical induced
animal model of colon cancer found the degree of tumor progression was directly
correlated with increasing amounts of HO-1 protein. This finding is in agreement with a
study of Korean colon cancer patients that found a higher level of HO-1 expression was
present in tumor tissues than in adjacent normal tissues (Kang, Maeng et al. 2012).
Clinical findings from several other studies appear to support the positive role of HO-1 in
colon cancer; demonstrating colonic HO-1 expression is associated with a greater long
term survival rate in colorectal cancer patients (Becker, Fukui et al. 2007; Andres,
Fermento et al. 2014). Researchers have conducted further analysis to explore the
mechanism involved in the anti-cancer effects of HO-1 in HCT116 p53wt and p53-/colon cancer cells. Results indicate the induction of cell-cycle arrest and apoptosis is
dependent upon a fully functioning p53 protein that also is associated with a requirement
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for increased p21 expression in order for the full expression of HO-1 and its’ apoptotic
effects to occur. Other research appears to support the integral role of a functioning p53;
Kalo et al have found that HO-1 displays an anti-apoptotic effect in Caco-2 colon cancer
cells with a mutant p53 and in other p53 mutant variants (Busserolles, Megias et al. 2006;
Kalo, Kogan-Sakin et al. 2012). Taken together, our research for the first time indicates
the combination of curcumin (5µM) and DDMN (7.5µM) results in a pronounced
increase in HO-1 expression that is also associated with the increased induction of p53
and p21 accompanied by increased apoptosis in HCT116 colon cancer cells.

3.7

Conclusion
In this study, curcumin and DDMN demonstrate synergism in combination as

compared to individual treatments for the decreased proliferation of HCT116 colon
cancer cells. These findings appear to be attributed to the G2/M cell-cycle arrest
exhibited after 24 hour treatment and dramatic induction of apoptosis following
prolonged 48 hour exposure of curcumin and DDMN in combination. Therefore, this
article reports for the first time that the combination of curcumin and DDMN, a primary
metabolite of nobiletin in the mouse, is synergistic in decreasing cell proliferation,
potentiating G2/M cell-cycle arrest and induction of apoptosis in HCT116 colon cancer
cells. In addition, our research suggests the involvement of p53, p21, HO-1, c-PARP,
cdc2 and cdc25c proteins in these enhanced anti-cancer effects of the combination
treatment. These significant findings warrant further investigation into the synergistic
properties and chemopreventive potential of curcumin and DDMN in combination for
colorectal cancer.
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CHAPTER 4
SYNERGISTIC ANTI-INFLAMMATORY EFFECTS OF CURCUMIN AND
FLAVONOID METABOLITE IN COMBINATION IN VITRO

4.1

Abstract

Chronic inflammation of the colon or inflammatory bowel disease (IBD) is associated
with an increased risk of developing colon cancer. Clinical studies suggest the longer the
duration of IBD and the higher the degree of inflammation the greater the colon cancer
risk. Effective long-term anti-inflammatory dietary strategies free of undesirable side
effects are urgently needed for the prevention of IBD-related colon cancer. Previously
we identified the synergistic interaction between curcumin and 3', 4' didemethylnobiletin
(DDMN) a primary metabolite of nobiletin in the mouse, to exhibit enhanced anticarcinogenic combinatory effects in HCT116 p53 wild-type colon cancer cells. A p53
mutation is an early event in inflammatory colon cancer and a defining event in the
adenoma to carcinoma transition of sporadic colon cancer; therefore in this study we
explored the anti-proliferative effects of the combination in HT29 colon cancer cells, a
p53 mutated cell line. To further characterize the synergism of this combination we also
examined the anti-inflammatory effects of DDMN (5µM-25µM), curcumin (3µM-15µM)
and their half- dose serial concentrations in combination at a 1.7:1 ratio in RAW 264.7
cells. Non-synergistic and diminished anti-proliferative effects were observed in the p53
mutated colon cancer cell line HT29 following combination treatment; whereas
isobologram analysis reveals a synergistic interaction exists between curcumin and
DDMN in the inhibition of LPS induced inflammation as evidenced by decreased NO
production in RAW 264.7 cells. The anti-inflammatory synergy between curcumin and
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DDMN offers a potential novel mechanism for the interaction of curcumin and nobiletin
in vitro and warrants further investigation.

4.2

Keywords:

Dietary bioactive components, combination, anti-inflammatory, colon cancer, flavonoid
metabolite, curcumin, nobiletin, synergistic, antagonistic, chronic intestinal inflammation

4.3

Abbreviations

DDMN: 3',4'-didemethylnobiletin; iNOS: inducible nitric oxide synthase; NO: nitric
oxide; IBD: inflammatory bowel disease; UC: ulcerative colitis; ROS: reactive oxygen
species; PMF: polymethoxyflavone; RNS: reactive nitrogen species; RONS: reactive
oxygen nitrogen species

4.4

Introduction
Inflammation has been reported to play a key role in the establishment or

progression of many diseases including atherosclerosis, obesity, arthritis, diabetes and
cancer. The prevalence of inflammation in such a broad array of chronic disease states
emphasizes the urgent need to develop anti-inflammatory diet-based strategies to alter the
course of disease. Acute inflammation can be protective of healthy cells, transitory and
self-limiting whereas chronic or long-term inflammation has been correlated with an
increased incidence of tumor development in epidemiological and clinical studies (Pal,
Bhattacharjee et al. 2014). Indeed, evidence suggests inflammation plays a prominent
role in the establishment and promotion of many cases of colon cancer (Lakatos and
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Lakatos 2008; Terzic, Grivennikov et al. 2010; Zhu and Li 2012). Inflammatory bowel
disease (IBD) or chronic intestinal inflammation has afflicted an estimated 3.1 million
Americans and appears to be occurring more frequently in the U.S. in recent years;
however the reason for this increase is not fully understood (Siegel, Miller et al. 2017).
Ulcerative colitis (UC) and Crohn’s disease are the two most frequently reported types of
IBD. Findings indicate the more colonic surface that is involved in the IBD-related
inflammation and the longer the duration of IBD the greater the colon cancer risk
(Itzkowitz and Yio 2004).
One of the leading theories of inflammation has involved the integral role of
oxidative stress in the development of cancerous growth in chronic inflammation. It is
this oxidative stress that is also associated with cellular damage and the pathogenesis of
IBD. Oxidative stress refers to the harmful effects of uncontrolled reactive oxygen
species (ROS) and reactive nitrogen species (RNS) accumulation to cells, also referred to
as reactive oxygen nitrogen species collectively (RONS). Normal cell processes involve
reactive oxygen species (ROS) at low levels (Kalo, Kogan-Sakin et al. 2012). Chronic
inflammation generates an accumulation of RONS or free radicals that can operate as
mutagenic agents in combination with increased cell proliferation and potentially bring
about oncogenic transformation in epithelial cells; DNA damaged cells may be allowed
to proceed through the cell cycle without being repaired to reproduce leading to
tumorigenesis (Mladenova and Kohonen-Corish 2012).
A mutation in the tumor suppressor gene p53 is found to occur frequently as an
early initiating event in inflammatory colon cancer and is also considered one of the
defining events in the promotion of an adenoma to a carcinoma in sporadic colon cancer,
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occurring in approximately 40-50% of diagnosed cases (Itzkowitz and Yio 2004; Li,
Zhou et al. 2015). A fully functioning p53 is important in apoptosis for the destruction of
cancer cells and suppression of the carcinogenic process; for this reason p53 is often
referred to as the “guardian of the genome”(Cooks, Harris et al. 2014). Accumulating
research suggests p53 is also important for the inhibition of inflammation (Gudkov,
Gurova et al. 2011). A high occurrence of p53 mutations have been reported in the
inflamed mucosa of ulcerative colitis (UC) patients that do not have cancer suggesting a
p53 mutation is associated with chronic inflammation of the colon (Hussain, Amstad et
al. 2000). Notably, in IBD when cancerous lesions are found they are typically located in
the colonic mucosa involved with inflammation (Rubin, Haggitt et al. 1992).
Current treatment modalities for chronic colon inflammation are limited due to
undesirable side effects associated with their long-term use. Research has shown diet to
be a powerful manipulator in the prevention and promotion of inflammation. Many
studies suggest individual dietary food components exhibit anti-inflammatory properties,
yet little research exists examining these dietary components in combination (BenaventeGarcia and Castillo 2008; Pan, Lai et al. 2009; Tunon 2009). Preliminary pre-clinical
studies appear to demonstrate synergistic anti-inflammatory effects in the combination of
dietary components (Hemalswarya 2006; Cheung, Khor et al. 2009).
Polymethoxyflavones (PMFs) are one such group of dietary bioactive components being
investigated; a class of citrus flavonoids found primarily in peels that have been credited
with operating in a variety of capacities including exhibiting potent anti-inflammatory
effects (Li, Lo et al. 2006; Walle 2007).
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Nobiletin, a polymethoxyflavone (PMF) of particular interest for its antiinflammatory effects, has shown significant inhibition of key proteins necessary for the
promotion of the inflammatory process (Murakami, Nakamura et al. 2000; Tanaka, Sato
et al. 2004; Harada, Tominari et al. 2011). Guo et al reports the combination of
nobiletin, (the parent compound of DDMN) and sulforaphane results in potent synergistic
anti-inflammatory effects in RAW 264.7 macrophage cells that include enhanced
inhibition of nitric oxide (NO) and expression of heme oxygenase-1 (HO-1) that is
greater than individual treatments (Guo, Qiu et al. 2012). Curcumin, the dietary
component found in turmeric, is well established for its anti-inflammatory properties and
has shown strong activity in the induction of HO-1 along with the inhibition of NO and
iNOS in RAW 264.7 macrophages (Kim, Pae et al. 2008). Synergistic anti-inflammatory
effects were observed in the combination of curcumin and sulforaphane in RAW 264.7
macrophages; the combination was found to synergistically down-regulate NO and
upregulate the induction of heme-oxygenase-1 (HO-1) (Cheung, Khor et al. 2009).
Although both nobiletin and curcumin have demonstrated synergism with sulforaphane in
RAW 264.7 cells, their anti-inflammatory effects in combination with each other have yet
to be explored.
Some researchers find the more potent anti-inflammatory effects of flavonoids are
associated with the metabolites rather than their parent compounds (Warner, Zhang et al.
2016). Interestingly, research examining 3',4'-didemethylnobiletin (DDMN), a major
metabolite of nobiletin in the mouse demonstrates anti-inflammatory effects with
decreased transcription of nitric oxide synthase (iNOS) when topically applied to a TPAinduced mouse skin inflammation model (Lai, Li et al. 2008). Indeed, DDMN was found
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to have stronger anti-inflammatory effects than nobiliten its parent compound in vitro
with suppression of LPS induced nitric oxide (NO) production and downregulation of
inducible nitric oxide synthase (iNOS).
Herein, to our knowledge this will be the first time DDMN and curcumin are
investigated in combination in HT29 p53 mutant colon cancer cells and RAW 264.7
macrophage cells, to further characterize the synergistic interaction observed between
DDMN and curcumin in HCT116 p53 wild-type colon cancer cells. This research will
aid in the determination of whether the synergistic anti-proliferative effects of DDMN
and curcumin in combination in HCT116 cells appear to utilize a p53-dependent or p53independent mechanism for the inhibition of colon cancer in vitro. In addition, the
investigation of an anti-inflammatory mechanism will be beneficial in establishing a basis
for nobiletin and curcumin in combination for future application with inflammatory colon
cancer and other inflammatory related diseases.

4.5

Materials and Methods

4.5.1

Cell Culture

HT29 cells were received from the American Type Culture Collection (ATCC, Manassas,
VA) and prepared as previously described; maintained in RPMI-1640 media with added
5% heat-inactivated fetal bovine serum (FBS). RAW 264.7 cells were obtained from the
American Type Culture Collection (ATTC, Rockville, MD) and cultured in RPMI-1640
media with added 10% heat-inactivated FBS (Medistech, Herndon, VA) along with 100
units/ml of penicillin, and 0.1 mg/mL of streptomycin (Sigma-Aldrich, St. Louis, MO) at
37 ͦ C with 5% CO2 and 95% air.
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4.5.2

Cell Treatments

Curcumin (96%) was obtained from Quality Phytochemicals, LLC (New Jersey, USA).
The 3', 4'-didemethylnobiletin (DDMN, 98%) was produced after a multi-step process
with its chemical structure verified using MS and NMR spectra methods as described (Li,
Pan et al. 2007; Li, Sang et al. 2007). DMSO was used for the delivery of DDMN and
curcumin to the cells in each experiment, resulting in a final concentration of 0.1%
DMSO.

4.5.3

Cell Viability Assay

HT-29 human colon cancer cells were seeded in 96-well plates (2000 cells per well) and
treatments of DDMN, curcumin or their combination were administered in serial
concentrations after 24 hour incubation. Once the associated treatment times were met,
the replacement of media with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) containing media (Sigma-Aldrich) was performed to quantify cell
viability. Further detail as outlined above and in prior experiments (Qiu, Dong et al.
2010).

4.5.4

Nitrite Assay

NO production by the Griess reaction will be determined by measuring the nitrite
concentration. The culture media will be mixed with an equal amount of Griess reagent
A at 1% sulfanilamide in 5% phosphoric acid and reagent B at 0.1%
naphthylethylenediamine dihydrochloride in water. The absorbance at 540 nm is read
using a plate reader (Elx800TM absorbance microplate reader, BioTek Instrument,
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Winooski, VT). The concentrations of nitrite will be calculated utilizing a standard curve
with sodium nitrite as a standard.

4.5.5

Analyses of Synergy

The analyses of synergy will be determined utilizing a linear regression model based on
the Chou Talahay method with some alterations as previously described (Chou and
Talalay 1984; Xiao, Zhang et al. 2008; Guo, Qiu et al. 2012). Results were examined
using the R program and synergy was categorized utilizing the interaction index
parameters with the combination interaction (CI) characterized as exhibiting additivity
(=1), synergy (<1), or antagonism (>1).

4.6 Results and Discussion
4.6.1

Curcumin and DDMN Demonstrate Synergism in the Inhibition of NO in

RAW 264.7 macrophage cells
To establish nontoxic dose ranges for DDMN and curcumin in RAW 264.7 cells;
the effects of these compounds were determined on cell viability utilizing the MTT assay
as previously described. We found that DDMN and curcumin concentrations up to 25µM
and 15µM respectively as well as their combined treatment did not cause a significant
decrease on the viability of RAW 264.7 cells. These nontoxic dose ranges were then
used to determine the inhibition of NO production by DDMN, curcumin and their
combination in LPS-stimulated RAW 264.7 macrophage cells. The cells were treated
with serial concentrations of DDMN (5µM-25µM) and curcumin (3µM-15µM)
individually and at half-dose serial concentrations in combination at a 1.7:1 ratio to
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determine nitric oxide (NO) inhibitory effects using the nitrite assay (Figure 4.1). NO
inhibition as measured by the nitrite assay revealed that combined treatment with DDMN
and curcumin, each at half-dose synergistically potentiated the NO inhibitory effects.
Individual treatment with DDMN alone exhibited a dose dependent response and
provided inhibition of NO (5%-45%) at all concentrations (5µM-25µM). Curcumin
individual treatment at concentrations (3µM-15µM) exhibited a dose dependent response
with a slightly stronger inhibition (5%-56%) of NO production than DDMN at similar
concentrations. Remarkably, the combination of DDMN and curcumin at half-dose serial
concentrations synergistically inhibited NO with a more pronounced effect (21%-56%)
than individual treatments as determined by the combination index previously described
in Section 2.3. Notably, combined treatments at the lower half-dose concentrations of
DDMN (2.5µM-5µM) and curcumin (1.5µM-2.5µM) exhibited the strongest synergy
with inhibition of NO production by the combination (21%-33%) more than doubling the
NO inhibition of each individual (5%-16%) treatment (Figure 4.2). Synergy was defined
as combination interaction index CI < 1.
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Figure 4.1 Percentage of inhibition on NO production by curcumin and DDMN
individually and in combination in LPS-stimulated RAW 264.7 macrophage cells. Cells
were treated with LPS as a positive control or LPS with serial concentrations of
curcumin, DDMN or their combination.
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Figure 4.2 (A) Median effect plot of DDMN, curcumin and their combination on
inhibition of NO production in LPS-stimulated RAW 264.7 macrophage cells. (B)
Interaction index plot for the combination effects of DDMN and curcumin on NO
production in LPS-stimulated RAW 264.7 macrophage cells. Synergy was defined as CI
interaction index < 1. Median effect plot and interaction index plot constructed as
described in Materials and Methods.
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4.6.2

Curcumin and DDMN Demonstrate Antagonism in the Inhibition of Cell

Viability in HT29 p53 Mutant Human Colon Cancer Cells
HT29 p53 mutant human colon cancer cells were treated with serial doses of
DDMN (3µM-15µM) and curcumin (2µM-10µM) individually and at half-dose serial
concentrations in combination to determine growth inhibitory effects using the MTT
assay. Cell viability as measured by the MTT assay revealed that combined treatment
with DDMN and curcumin displayed growth inhibitory effects after 48 hours of
compound exposure (Figure 4.3). Individual treatment with DDMN alone provided only
minimal inhibition of growth (4%-12%) at low concentrations (3µM-6µM) but was
substantially more effective at inhibition of growth (35%) with the highest concentration
(15µM). Curcumin individual treatment exhibited a dose dependent response with a
much stronger inhibition (25%-56%) of growth at concentrations 6µM-10µM as
compared to DDMN at similar concentrations. The combination of DDMN and
curcumin at half-dose serial concentrations inhibited cell viability in a dose dependent
manner with an additive effect at lower concentrations of 3µM-5µM + 1µM-2µM
respectively that appeared to not greatly differ from the individual treatment effects.
Combination of DDMN and curcumin at higher concentrations of 4.5µM-7.5µM + 3µM5µM respectively exhibited an antagonistic effect of less inhibition of growth than the
individual treatments, as determined by the combination index previously described
(Figure 4.4). Additive was defined as combination interaction index CI=1. Antagonism
was defined as combination interaction index CI > 1.
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Figure 4.3 Growth inhibitory effects of curcumin and DDMN individually and in
combination following serial concentrations of compound treatments in HT29 p53 mutant
human colon cancer cells. Cell viability was measured by MTT assay as previously
described in Section 2.3.
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Figure 4.4 Combined treatment with curcumin and DDMN exhibited additive and
antagonistic growth inhibitory effects in HT29 p53 mutant human colon cancer cells after 48
hr of compound exposure. (A) Median effect plot of curcumin, DDMN and their
combination on growth inhibition of HT29 p53 mutant cells. (B) Interaction index plot for
the combination effects of curcumin and DDMN on growth inhibitory effects of HT29 p53
mutant colon cancer cells. Antagonism was defined as CI interaction index > 1. Median
effect plot and interaction index plot constructed as described in Materials and Methods.
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4.6.3 Discussion
Many factors point to the importance of addressing chronic intestinal
inflammation both preventively and early in treatment, as progression to colon cancer is
more likely to occur in cases with an earlier onset of disease, prolonged duration and
severity of inflammation; each greatly increasing the risk of developing colon cancer
(Terzic, Grivennikov et al. 2010; Jawad, Direkze et al. 2011). As of this date, a cure
remains elusive and pharmaceutical drugs have been limited in their capability to alter the
disease process (Lakatos and Lakatos 2008). The inflammatory progression of IBD often
leads to unwanted surgery, complications and serious side effects associated with the
drugs used to treat advanced stages of IBD. An accumulating body of research suggests
dietary components exhibit anti-inflammatory properties within the same deregulated
signaling pathways as chronic intestinal inflammation yet without the unwanted side
effects; offering a viable alternative for the prevention and treatment of intestinal
inflammation (Benavente-Garcia and Castillo 2008; Pan, Lai et al. 2009). Moreover,
using dietary components in combination offers the potential for a synergistic interaction,
thereby eliciting a more powerful anti-inflammatory response with low toxicity.
Nobiletin and curcumin each have shown significant anti-inflammatory properties
individually in cellular and animal models (Murakami, Nakamura et al. 2000; Tanaka,
Sato et al. 2004; Harada, Tominari et al. 2011). Recently we demonstrated a primary
metabolite of nobiletin, 3',4' – didemethylnobiletin (DDMN) and curcumin were
synergistic in the inhibition of cell growth in HCT116 colon cancer cells. In this study
our findings of decreased nitric oxide (NO) production in LPS stimulated RAW 264.7
cells by individual DDMN or curcumin treatment are consistent with research conducted
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by others however the anti-inflammatory effects of DDMN and curcumin in combination
to our knowledge have not yet been examined (Li, Sang et al. 2007; Kim, Pae et al. 2008;
Cheung, Khor et al. 2009). Therefore, we report for the first time on the synergistic antiinflammatory inhibition of NO production by the combination of DDMN and curcumin
in LPS stimulated RAW 264.7 macrophage cells. NO inhibition is an important target for
the prevention of chronic intestinal inflammation and IBD-related colon cancer as IBD is
characterized by elevated levels of inducible NO synthase (iNOS) resulting in high levels
of nitric oxide (NO). Indeed, inducible NO synthase (iNOS) is elevated in both inflamed
colonic mucosa and in colonic tumors (Hussain, Amstad et al. 2000). Peroxynitrate a
product of the reaction of superoxide and nitric oxide (NO) is correlated with colonic
inflammation and IBD type pathogenesis in vivo (Zhu and Li 2012).
This study for the first time has shown the combination of DDMN and curcumin
in half-dose serial concentrations results in synergistic inhibition of NO production in
LPS stimulated RAW 264.7 macrophage cells. Surprisingly, the lower half-dose
concentrations of DDMN (2.5µM-5µM) + curcumin (1.5µM-2.5µM) in combination
exhibited the greatest synergism; therefore a saturation or ceiling appears to potentially
exist at which higher concentrations of the compounds are not as potent or efficacious in
their anti-inflammatory effects when combined. Excitingly, the enhanced antiinflammatory effect of the lower dose combinations provides an opportunity for further
investigation as an effective small dose for a prolonged period of time with low toxicity
would be of great benefit for those with inflammation related diseases for the inhibition
of NO production.
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The relationship between NO and p53 appears to be pivotal in determining the
outcome of inflammation and tumorigenesis. Researchers suggest NO can be protective
at early stages of chronic inflammation from IBD-related colon cancer before alteration
of the p53 protein is involved (Goodman, Hofseth et al. 2004). As such, p53 under low
stress conditions has been found to be protective from NO induced DNA damage when
activation is triggered by iNOS and the production of NO in the colons of UC patients
facilitates a negative feedback loop with p53 (Hofseth, Saito et al. 2003). Nitric oxide
appears to have opposing roles, acting either as pro-tumorigenic or anti-tumorigenic
depending on the status of p53. The negative feedback loop of p53 and NO is comprised
with NO initiating the accumulation of p53 which then leads to the suppression of iNOS
thereby limiting NO production (Forrester, Ambs et al. 1996; Ambs, Ogunfusika et al.
1998). The increased p53 activity leads to apoptosis, cell cycle arrest and the elimination
of damaged cells promoting anti-tumorigenesis. In cells lacking a wild-type p53, NO
production leads to cell proliferation as a result of cells no longer taking part in apoptosis
and cell cycle arrest. In mice without p53 when iNOS is deleted sarcomas and lymphoma
are reduced suggesting the negative feedback loop of p53 and NO is involved in the
regulation of tumorigenesis (Hussain, Trivers et al. 2004; Tatemichi, Tazawa et al. 2004).
P53 also plays the role of antagonist in the inflammatory process. The nuclear
factor-kappa B (NF-κB) pathway is the primary regulator of both acute and chronic
inflammation (Ben-Neriah and Karin 2011). Gudkov et al identifies p53 as an antagonist
of NF-κB resulting in the inhibition of inflammation (Gudkov and Komarova 2016). The
relationship between p53 and NF-κB has been described as generally antagonistic in most
cell systems with both participating in a cross talk regulated by multiple mechanisms that
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are still not fully defined (Schneider and Kramer 2011). NF-κB is activated and present
in biopsies of inflamed mucosa of IBD patients and can trigger iNOS to produce NO with
its pro-inflammatory and potential carcinogenic effects (Rogler, Brand et al. 1998;
Yamamoto and Gaynor 2001). Inhibition of NF-κB activity in inflammation associated
colon cancer mouse models halts tumor growth and suppresses tumors in xenograft
studies (Gurova, Hill et al. 2005; Gasparian, Burkhart et al. 2011; Sunami and Wirth
2011; Vlantis, Wullaert et al. 2011). Interestingly, nobiletin was shown to inhibit the
DNA binding of the pro-inflammatory transcription factor NFκB in LPS stimulated RAW
264.7 macrophage cells and prevent the nuclear NFκB translocation from the cytoplasm
and its expression into the nucleus in BV-2 microglia cells, a neuroinflammation model.
(Choi, Hwang et al. 2007; Cui, Wu et al. 2010). It is the deregulation of NF-κB at any
point in the NF-κB pathway that is attributed with the constant activation of NF-κB
leading to chronic inflammation and the potential transformation to cancer (Balkwill and
Coussens 2004; Lin and Karin 2007; Natarajan, Komarov et al. 2014). P53 has proven to
have the capacity to suppress the activity of NF-κB resulting in the attenuation of
inflammation and its effects; likewise deregulation of NF-κB as observed in chronic
inflammation can suppress p53 and its’ role as a tumor suppressor (Gudkov and
Komarova 2016).
As evidence suggests p53 plays a key role in the regulation of chronic intestinal
inflammation and tumorigenesis, a p53 mutation can have broad negative effects on the
IBD pathogenesis and colon cancer development. Mutation of the p53 protein results in
the loss of its tumor suppressor role and a gain of new functions that include increased
cell proliferation and the promotion of oncogenic transformation and invasiveness.
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Cooks et al demonstrates an extended and magnified activation of the inflammatory
response by mutated p53 in addition to the absence of anti-inflammatory properties
frequently observed in the non-mutated wild-type p53 (Cooks, Pateras et al. 2013).
Free radicals are generated in the inflammatory process potentially targeting
genes and proteins important for homeostasis of colonocytes. Upon excessive ROS and
free radical accumulation in cells a protective mechanism activates the transcription of a
number of detoxifying enzymes that includes heme-oxygenase-1 (HO-1) which in turn
inactivates the ROS halting any further damaging effects (Kalo, Kogan-Sakin et al.
2012). Heme-oxygenase-1 an inducible phase II enzyme, has been characterized as an
endogenous inflammatory regulator, as such HO-1 knockout mice develop chronic
inflammatory disease (Paine, Eiz-Vesper et al. 2010). Lipopolysaccharide (LPS)
stimulated macrophages induce (HO-1) which decreases inflammatory indicators of NO,
iNOS and COX-2. Interestingly, HO-1 mRNA and protein expression have been
identified in intestinal cell lines and human IBD tissue samples, suggestive of an innate
protective response that exists to limit tissue damage through the release of HO-1 (Paine,
Eiz-Vesper et al. 2010).
The p53 protein can be targeted by these free radicals and ROS accumulation if
left unchecked resulting in p53 mutations early in the pathogenesis of IBD; p53
mutations occur at a higher rate in the inflamed mucosa of IBD patients shifting the
progression of inflammation to one of dysplasia and increased risk of colon cancer
development (Matkowskyj, Chen et al. 2013). This sequence can be described as the
“inflammation-dysplasia-carcinoma” sequence characteristic in IBD. The degree of IBD
related dysplasia to carcinoma appears to correlate with the level of p53 mutations
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(Gerrits, Chen et al. 2011). The changes in p53 early in the pathogenesis of IBD suggest
it is an effective marker for screening of chronic inflammation of the colon and
subsequent risk of colon cancer development (Matkowskyj, Chen et al. 2013).
The role of p53 in chronic inflammation and carcinogenesis is complex and multifaceted. This study is the first to report on the non-synergistic anti-proliferative effects of
DDMN in combination with curcumin in the p53 mutant cell line HT29; findings indicate
no interaction (additive) occurred at low combinatory concentrations of DDMN at
1.5µM-3µM + curcumin at 1µM-2µM whereas an antagonistic combination response
with a reduction in anti-proliferative effects appears to exist at higher concentrations of
DDMN (4.5µM-7.5µM) curcumin (3µM-5µM). These findings are in contrast to our
results in the p53 wild type cell line HCT116 in which the combination demonstrated
synergistic anti-proliferative effects. Our findings suggest two different mechanisms are
at work in HT29 p53 mutated cells, one an additive interaction at low concentrations of
DDMN + curcumin and the other an antagonistic interaction at higher concentrations of
the combination. Others have reported differing mechanisms involved in curcumin’s
anti-cancer effects that are concentration based, with low concentrations of curcumin
exhibiting an antioxidant effect and higher concentrations of curcumin demonstrating a
pro-apoptotic effect (Park and Conteas 2010).
Research examining apoptosis following curcumin treatment and the role of p53
has had mixed findings (Jee, Shen et al. 1998; Choudhuri, Pal et al. 2002; Radhakrishna
Pillai, Srivastava et al. 2004; Watson, Hill et al. 2008; Watson, Hill et al. 2010). Watson
et al suggests curcumin utilizes a p-53 independent mechanism to promote apoptosis in
HCT116 colon cancer cells. Other researchers compared curcumin sensitivity in p53
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wild type HCT116 colon cancer cells with a p53 knockout HCT116 cell line to conclude
that wild type p53 is required for curcumin sensitivity (Howells, Mitra et al. 2007).
Interestingly, clinical findings following curcumin treatment in colorectal cancer patients
suggest a correlation exists between an increased expression of p53 in tumor tissue with
an increase in apoptotic tumor cells and increased body weight (He, Shi et al. 2011).
Our prior study demonstrated extensive induction of apoptosis and a significant
increase in p53 and HO-1 expression was associated with the synergistic inhibition of cell
growth by the combination of DDMN (7.5µM) + curcumin (5µM) in HCT116 p53 wild
type colon cancer cells. Indeed, the full dose combination treatment of DDMN (7.5µM)
+ curcumin (5µM) exhibited a substantial 110% increase in p53 expression as compared
to control, resulting in a much stronger response than individual curcumin (70%) or
DDMN (10%) treatments. Likewise, heme oxygenase-1 (HO-1), a phase 2 enzyme
induced in response to oxidative stress was found to dramatically increase following our
treatment of HCT116 p53 wild type colon cancer cells with DDMN (7.5µM), curcumin
(5µM) or full dose combination treatment increasing HO-1 expression by 490%, 10% and
770% respectively. Researchers have explored the mechanism involved in the apoptotic
and anti-cancer effects of HO-1 in HCT116 p53wt and p53-/- colon cancer cells. Results
indicate the induction of apoptosis is dependent upon a fully functioning p53 protein in
order for the full expression of HO-1 and its’ apoptotic effects to occur. Other research
appears to support the integral role of a functioning p53. Kalo et al have found that HO-1
displays an anti-apoptotic effect in Caco-2 p53 mutant colon cancer cells and in other p53
mutant variants (Busserolles, Megias et al. 2006; Kalo, Kogan-Sakin et al. 2012).
Mutated p53 has also been associated with a reduction in phase II enzymes such as HO-
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1and a resistance to cellular death. Taken together these findings suggest that HO-1 and
p53 play an important role in the synergism of DDMN and curcumin in combination in
HCT116 p53 wild type colon cancer cells and potentially can contribute in part to explain
the differing antagonistic combination response in HT29 p53 mutant colon cancer cells.

4.7

Conclusions

In conclusion, this study for the first time has shown that the combination of DDMN and
curcumin synergistically inhibits LPS-induced inflammation in RAW 264.7 macrophage
cells as demonstrated by the inhibition of nitric oxide (NO) production. In addition, for
the first time we have identified a non-synergistic interaction occurs in the combination
of DDMN and curcumin in HT29 p53 mutant colon cancer cells resulting in diminished
anti-proliferative effects that are less than individual treatments. Our results provide new
insights into the characterization of the synergistic combination of DDMN and curcumin
in HCT116 p53 wild-type colon cancer cells. The synergistic anti-cancer activity of this
combination could be in part due to its mode of action in its ability to induce p53 in
HCT116 colon cancer cells perhaps resulting in the inhibition of inflammatory pathways
and the promotion of apoptosis. Further investigation is warranted for the development
of new dietary combination strategies that will disrupt the transformation of chronic
inflammation to potentially prevent and reduce the occurrence of IBD-related colon
cancer.
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CHAPTER 5
CONCLUSIONS

Research has shown diet to be a powerful manipulator in the prevention and
promotion of cancer and inflammation. Excitingly, many studies suggest dietary
components exhibit anti-cancer and anti-inflammatory properties with low or no toxicity,
yet little research exists examining these dietary components in combination. As we do
not eat these compounds in isolation it is important to examine the interaction of dietary
components when combined; examination of the biological activities and interactions of
their metabolites with other dietary components can aid in eliciting a better understanding
of the possible mechanisms involved in vivo.
Although numerous studies show that complementary mechanisms of individual
dietary components can result in enhanced anti-cancer and anti-inflammatory effects
when used in combination, caution is warranted as certain dietary component
combinations can be antagonistic with diminished anti-cancer or anti-inflammatory
effects and in some instances can even act as a promoter of carcinogenesis. In these
cases, it is critical to understand how these components interact within the particular
combinations so that recommendations can be made to avoid potential adverse effects.
These findings underscore the need to further investigate and characterize new dietary
component combination strategies that have the potential to elicit a more potent
synergistic anti-cancer and anti-inflammatory response for cancer chemoprevention and
inflammation.
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